<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003113.pub2" GROUP_ID="MUSKEL" ID="409301022714025286" MERGED_FROM="" MODIFIED="2011-10-03 07:36:20 +0200" MODIFIED_BY="Renea Johnston" REVIEW_NO="C141-P" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2011-10-03 07:36:20 +0200" MODIFIED_BY="Renea Johnston">
<TITLE>Opioid therapy for treating rheumatoid arthritis pain</TITLE>
<CONTACT MODIFIED="2011-10-03 07:36:20 +0200" MODIFIED_BY="Renea Johnston"><PERSON ID="AF14351D82E26AA2013849DF4DEC1849" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Samuel</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Whittle</LAST_NAME><SUFFIX>MBBS(Hons) FRACP</SUFFIX><POSITION>Staff Specialist</POSITION><EMAIL_1>Samuel.Whittle@health.sa.gov.au</EMAIL_1><EMAIL_2>samuelwhittle@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Rheumatology Unit</DEPARTMENT><ORGANISATION>The Queen Elizabeth Hospital</ORGANISATION><ADDRESS_1>28 Woodville Road</ADDRESS_1><CITY>Woodville</CITY><ZIP>5011</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+618 8222 6688</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-10-03 07:36:20 +0200" MODIFIED_BY="Renea Johnston"><PERSON ID="AF14351D82E26AA2013849DF4DEC1849" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Samuel</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Whittle</LAST_NAME><SUFFIX>MBBS(Hons) FRACP</SUFFIX><POSITION>Staff Specialist</POSITION><EMAIL_1>Samuel.Whittle@health.sa.gov.au</EMAIL_1><EMAIL_2>samuelwhittle@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Rheumatology Unit</DEPARTMENT><ORGANISATION>The Queen Elizabeth Hospital</ORGANISATION><ADDRESS_1>28 Woodville Road</ADDRESS_1><CITY>Woodville</CITY><ZIP>5011</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+618 8222 6688</PHONE_1></ADDRESS></PERSON><PERSON ID="03442282744761941081100408063946" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bethan</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Richards</LAST_NAME><SUFFIX>MBBS</SUFFIX><POSITION>Rheumatology Registrar</POSITION><EMAIL_1>brichard@med.usyd.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Rheumatology</DEPARTMENT><ORGANISATION>Royal Prince Alfred Hospital</ORGANISATION><ADDRESS_1>Missenden Road</ADDRESS_1><CITY>Camperdown</CITY><ZIP>2050</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+612 98173779</PHONE_1><FAX_1>+612 98176753</FAX_1></ADDRESS></PERSON><PERSON ID="14950" ROLE="AUTHOR"><FIRST_NAME>Elaine</FIRST_NAME><LAST_NAME>Husni</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Director, Clinical Outcomes Research</POSITION><EMAIL_1>husnie@ccf.org</EMAIL_1><ADDRESS><DEPARTMENT>Department of Rheumatic and Immunologic Diseases</DEPARTMENT><ORGANISATION>Cleveland Clinic: Orthopedic and Rheumatologic Institute</ORGANISATION><ADDRESS_1>9500 Euclid Ave- A50</ADDRESS_1><CITY>Cleveland</CITY><ZIP>44195</ZIP><REGION>OH</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>1-216-445-1853</PHONE_1><FAX_1>1-216-445-7569</FAX_1></ADDRESS></PERSON><PERSON ID="4495" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Rachelle</FIRST_NAME><LAST_NAME>Buchbinder</LAST_NAME><SUFFIX>MBBS (Hons) MSc PhD FRACP</SUFFIX><POSITION>Director</POSITION><EMAIL_1>rachelle.buchbinder@monash.edu</EMAIL_1><ADDRESS><DEPARTMENT>Monash Department of Clinical Epidemiology at Cabrini Hospital</DEPARTMENT><ORGANISATION>Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University</ORGANISATION><ADDRESS_1>Suite 41, Cabrini Medical Centre</ADDRESS_1><ADDRESS_2>183 Wattletree Road</ADDRESS_2><CITY>Malvern</CITY><ZIP>3144</ZIP><REGION>Victoria</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>613 9508 1652</PHONE_1><PHONE_2>613 9509 4445</PHONE_2><FAX_1>613 9508 1653</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-03-29 14:15:38 +1100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="4" MONTH="5" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="5" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="1" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2011-03-29 14:14:07 +1100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-10 14:55:13 +1100" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to RevMan5. CMSG ID C141-P</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2010-10-25 18:14:53 +1100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-10-25 18:14:53 +1100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-10-25 14:38:49 +1100" MODIFIED_BY="[Empty name]">
<NAME>Cabrini Hospital</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>In kind support</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2010-10-25 14:39:11 +1100" MODIFIED_BY="[Empty name]">
<NAME>Monash University</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>In kind support</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2010-10-25 18:13:56 +1100" MODIFIED_BY="[Empty name]">
<NAME>The Queen Elizabeth Hospital</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>In kind support</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2010-10-25 18:14:53 +1100" MODIFIED_BY="[Empty name]">
<NAME>Royal Prince Alfred Hospital</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>In kind support</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-09-18 15:54:55 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-09-17 22:37:01 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-01-06 10:37:04 +1100" MODIFIED_BY="[Empty name]">Opioid therapy for treating rheumatoid arthritis pain </TITLE>
<SUMMARY_BODY MODIFIED="2011-09-17 22:37:01 +1000" MODIFIED_BY="[Empty name]">
<P>This summary of a Cochrane review presents what we know from research about the effect of opioids for treating rheumatoid arthritis pain.</P>
<P>
<B>The review shows that in people with rheumatoid arthritis treated with weak opioids for up to six weeks:</B>
</P>
<P>- Weak opioids may reduce pain compared with placebo</P>
<P>- Treatment with weak opioids may result in more side-effects compared with placebo.</P>
<P>There were no studies in people with rheumatoid arthritis that looked at the effects of weak opioids taken for more than six weeks. There were not enough studies of strong opioids to draw conclusions about their effects in rheumatoid arthritis.</P>
<P>
<B>What is rheumatoid arthritis and what are opioids?</B>
</P>
<P>When you have rheumatoid arthritis your immune system, which normally fights infection, attacks the lining of your joints. This makes your joints swollen, stiff and painful. The small joints of your hands and feet are usually affected first. There is no cure for rheumatoid arthritis at present, so the treatments aim to relieve the pain and stiffness and improve your ability to move.</P>
<P>Opioids are powerful pain-relieving substances that range in strength from relatively mild, such as codeine, to strong, such as morphine. Some examples of weak opioids are codeine (for example Panadeine Forte®) and tramadol (for example Tramal). Some examples of strong opioids are oxycodone (for example Percocet, Endone), morphine and fentanyl (for example Duragesic). They can be taken in a pill form, as an injection or as a patch placed on the skin. Common opioid side-effects include nausea, constipation and drowsiness.</P>
<P>
<B>Best estimate of what happens to people with rheumatoid arthritis who take opioids</B>
</P>
<P>
<I>Patient-reported global impression of change</I>
</P>
<P>-18 more people out of 100 reported a 'good' or 'very good' improvement in the symptoms of their rheumatoid arthritis after treatment with opioids for between one and six weeks (18% absolute improvement)</P>
<P>-57 people out of 100 reported a 'good' or 'very good' improvement in symptoms</P>
<P>-40 people out of 100 who took a placebo reported a 'good' or 'very good' improvement in symptoms</P>
<P>
<I>Side-effects</I>
</P>
<P>-30 more people out of 100 experienced at least one side-effect during treatment with opioids for between one and six weeks (30% absolute difference)</P>
<P>-51 people out of 100 had at least one side-effect</P>
<P>-21 people out of 100 who took a placebo had at least one side-effect</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-09-17 22:27:11 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-09-17 22:18:07 +1000" MODIFIED_BY="[Empty name]">
<P>Despite improvements in the management of rheumatoid arthritis (RA), pain control is often inadequate even when inflammation is well controlled.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-03-24 11:44:39 +1100" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy and safety of opioid analgesics for treating pain in patients with RA.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-09-17 22:23:36 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>), MEDLINE and EMBASE for studies to May 2010. We also searched the 2008 to 2009 American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) abstracts and performed a handsearch of the reference lists of articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-03-24 12:09:23 +1100" MODIFIED_BY="[Empty name]">
<P>Studies were included if they were randomized or quasi-randomized controlled trials (RCTs or CCTs) which compared opioid therapy to another therapy (active or placebo) for pain in patients with RA. Outcomes of interest were pain, adverse effects, function and quality of life.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-01-04 17:39:38 +1100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently selected the studies for inclusion, extracted the data, and performed a risk of bias assessment. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-09-17 22:27:11 +1000" MODIFIED_BY="[Empty name]">
<P>Eleven studies (672 participants) were included in the review. Four studies assessed the efficacy of single doses of various opioid and non-opioid analgesics; a pooled analysis of these studies was not performed but in each study opioids reduced pain more than placebo. There were no differences between analgesic drugs in these studies.</P>
<P>Seven studies were between one and six weeks in duration and assessed six different oral opioids (dextropropoxyphene, codeine, tramadol, tilidine, pentazocine, morphine), either alone or combined with non-opioid analgesics. The only strong opioid investigated was controlled-release morphine sulphate, in a single study with 20 participants. Six studies compared an opioid to placebo. Opioids were superior to placebo in patient-reported global impression of change (3 studies, 324 participants: relative risk (RR) 1.44, 95% CI 1.03 to 2.03) but not for the number of withdrawals due to inadequate analgesia (4 studies, 345 participants: RR 0.82, 95% CI 0.34 to 2.0). Adverse events (most commonly nausea, vomiting, dizziness and constipation) were more frequent in patients receiving opioids compared to placebo (4 studies, 371 participants: odds ratio 3.90, 95% CI 2.31 to 6.56); the pooled risk ratio for withdrawal due to adverse events was 2.67 (3 studies, 331 participants: 95% CI 0.52 to 13.75). One study compared an opioid (codeine with paracetamol) to an NSAID (diclofenac) and found no difference in efficacy or safety between interventions.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-09-06 16:36:43 +1000" MODIFIED_BY="[Empty name]">
<P>There is limited evidence that weak oral opioids may be effective analgesics for some patients with RA, but adverse effects are common and may offset the benefits of this class of medications. There is insufficient evidence to draw conclusions regarding the use of weak opioids for longer than six weeks, or the role of strong opioids.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-09-18 15:53:13 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-09-17 22:47:11 +1000" MODIFIED_BY="[Empty name]">
<P>Rheumatoid arthritis (RA) is a chronic, inflammatory, destructive joint disease that affects about 1% of the population (<LINK REF="REF-Alarcon-1995" TYPE="REFERENCE">Alarcon 1995</LINK>). RA can cause progressive joint destruction and deformity despite state-of-the-art treatment.</P>
<P>The mainstays of therapy in RA, disease-modifying anti-rheumatic drugs (DMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs), primarily target inflammatory pathways, however there are multiple contributors to the genesis of pain in RA in addition to inflammation, including joint damage or destruction and peripheral and central sensitization (<LINK REF="REF-McDougall-2006" TYPE="REFERENCE">McDougall 2006</LINK>), which may not be responsive to treatment with these medications. Indeed, despite recent improvements in the management of RA, including earlier intervention, more aggressive use of DMARDs and the advent of the biologic disease-modifying therapies (bDMARDs), many patients with RA continue to experience musculoskeletal pain even when inflammation is well-controlled (<LINK REF="REF-Kvien-2004" TYPE="REFERENCE">Kvien 2004</LINK>). Patients with RA perceive pain to be their predominant impairment (<LINK REF="REF-Minnock-2003" TYPE="REFERENCE">Minnock 2003</LINK>) and report pain management as their highest priority (<LINK REF="REF-Heiberg-2002" TYPE="REFERENCE">Heiberg 2002</LINK>). Although opioids have been claimed to successfully control pain in RA, the potential for adverse effects, addiction and drug interactions has limited their regular use (<LINK REF="REF-Fitzcharles-2009" TYPE="REFERENCE">Fitzcharles 2009</LINK>).</P>
<P>Opioids produce their pharmacological effects via interaction with receptors located on neuronal cell walls. The synthetic analgesic tramadol combines an opioid receptor effect with monoamine reuptake inhibition (<LINK REF="REF-Raffa-1992" TYPE="REFERENCE">Raffa 1992</LINK>). Opioids are commonly classified as either 'weak' or 'strong', however no consensus exists for such a classification and there is no clear pharmacological distinction at the receptor level between drugs to which either of these labels are commonly applied. Opioids classified as 'weak' tend to have maximal doses beyond which further escalation results in no increase in analgesic effect, or the onset of intolerable adverse effects, and are often administered as fixed dose combinations with non-opioid analgesics such as paracetamol (<LINK REF="REF-Goldman-2006" TYPE="REFERENCE">Goldman 2006</LINK>).</P>
<P>Because the analgesic properties of opioids do not depend on the presence of active inflammation, they are theoretically attractive as an analgesic option in RA patients with persistent pain despite the use of DMARDs. The presence of opioid receptors on peripheral afferent nerves within joints suggests that opioids may have peripheral analgesic effects in RA in addition to their effect on the CNS (<LINK REF="REF-Lang-2010" TYPE="REFERENCE">Lang 2010</LINK>). In addition, intra-articular nociceptive nerve fibres may contribute to joint inflammation via the release of neuropeptides such as substance P and calcitonin gene-related peptide, which raises the possibility that opioids may also act to inhibit joint inflammation (<LINK REF="REF-Fields-1980" TYPE="REFERENCE">Fields 1980</LINK>; <LINK REF="REF-McDougall-2006" TYPE="REFERENCE">McDougall 2006</LINK>).</P>
<P>The role of opioids in the management of acute pain, post-surgical pain and chronic cancer pain is clearly established (<LINK REF="REF-Hudcova-2006" TYPE="REFERENCE">Hudcova 2006</LINK>; <LINK REF="REF-Wiffen-2007" TYPE="REFERENCE">Wiffen 2007</LINK>). However, the role of opioid therapy for chronic non-cancer pain remains an area of debate. There is weak evidence that opioids may provide clinically significant pain relief in a proportion of individuals with chronic non-cancer pain, however many patients discontinue treatment due to adverse effects (<LINK REF="REF-Noble-2010" TYPE="REFERENCE">Noble 2010</LINK>). Although opioids are frequently used for the management of pain in RA sufferers (<LINK REF="REF-Grijalva-2008" TYPE="REFERENCE">Grijalva 2008</LINK>), current RA treatment guidelines offer scant guidance regarding the use of opioids in an evidence-based management algorithm (<LINK REF="REF-ACR-2002" TYPE="REFERENCE">ACR 2002</LINK>; <LINK REF="REF-Luqmani-2009" TYPE="REFERENCE">Luqmani 2009</LINK>). There is a large unmet need for safe and effective analgesic medications in this population, and this systematic review seeks to examine the evidence regarding the role of opioids in the management of RA pain.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-09-17 15:56:57 +1000" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy and safety of opioid analgesics for treating pain in patients with RA.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-09-18 15:33:56 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-09-18 15:33:56 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-09-17 22:48:16 +1000" MODIFIED_BY="[Empty name]">
<P>All published randomized or quasi-randomized controlled trials (RCTs or CCTs) which compared opioid therapy to another therapy (placebo or active including non-pharmacological therapies) for RA were considered for inclusion.</P>
<P>Studies of opioid therapy in RA in the immediate post-operative setting (for example after arthroplasty or arthroscopy) and studies that did not contain pain as an outcome measure were excluded.</P>
<P>Only trials published as full articles or available as a full trial report were considered for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-08-31 12:48:32 +1000" MODIFIED_BY="[Empty name]">
<P>Adult patients (aged 18 years or older) with a diagnosis of RA. Populations that included a mix of people with RA and other musculoskeletal pain were excluded unless results for the RA population could be separated out from the analysis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-09-18 13:37:06 +1000" MODIFIED_BY="[Empty name]">
<P>All trials that evaluated opioid medications were included. This includes tramadol and compound medications where an opioid is combined with a simple analgesic (such as codeine combined with paracetamol). Opioid administration via any route (including, but not limited to, oral, transdermal and intra-articular), any formulation (for example immediate-acting or sustained-release), and any interval (for example on-demand or at regular intervals) was included. Despite the lack of consensus regarding the boundary between 'weak' and 'strong' opioids, the persistence of these descriptors in clinical practice suggests that clinicians and regulatory bodies find such a distinction to be a useful conceptual tool and we elected to retain such a classification. For the purpose of this review, we considered 'weak opioids' to include codeine, tramadol, (dextro)propoxyphene, pentazocine and tilidine. 'Strong opioids' included morphine, oxycodone, methadone, fentanyl, hydromorphone, buprenorphine and diamorphine.</P>
<P>Comparators could be:</P>
<P>1. placebo;</P>
<P>2. a different opioid analgesic;</P>
<P>3. non-opioid analgesic medications (including NSAIDs, paracetamol, neuromodulators and antidepressants, but excluding DMARDs and bDMARDs);</P>
<P>4. non-pharmacological analgesic modalities (e.g. acupuncture, massage, transcutaneous electrical nerve stimulation (TENS));</P>
<P>5. The same opioid medication via a different route, formulation or dosing interval.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-09-18 15:33:56 +1000" MODIFIED_BY="[Empty name]">
<P>There is considerable variation in the outcome measures reported in clinical trials of interventions for pain. For the purpose of this systematic review, we aimed to include outcome measures that are considered to be of the greatest importance to patients with persistent pain and the clinicians who care for them. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) has published consensus recommendations for determining clinically important changes in outcome measures in clinical trials of interventions for chronic pain. Reductions in pain intensity of &#8805; 30% and &#8805; 50% reflect moderate and substantial clinically important differences, respectively, and it is recommended that the proportion of patients that respond with these degrees of pain relief be reported (<LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>).</P>
<P>Continuous outcome measures in pain trials (such as mean change on a 100 mm visual analogue scale) may not follow a Gaussian distribution. Often, a bimodal distribution is seen instead, where patients tend to report either very good or very poor pain relief (<LINK REF="REF-Moore-2010a" TYPE="REFERENCE">Moore 2010a</LINK>). This creates difficulty in interpreting the meaning of average changes in continuous pain measures. For this reason, a dichotomous outcome measure (the proportion of participants reporting &#8805; 30% pain relief) is likely to be more clinically relevant and was the primary efficacy measure in this review. It is recognised, however, that it has been the practice in most trials of interventions for chronic pain to report continuous measures and therefore the mean change in pain score was also included as a secondary efficacy measure.</P>
<P>The pain state at the end of a clinical trial of an analgesic intervention, in contrast to measures of pain improvement, has also been recommended as a clinically relevant dichotomous outcome measure and was included as a secondary efficacy measure in this review (<LINK REF="REF-Moore-2010a" TYPE="REFERENCE">Moore 2010a</LINK>). A global rating of treatment satisfaction, such as the Patient Global Impression of Change scale (PGIC) which provides an outcome measure that integrates pain relief, changes in function and side-effects into a single, interpretable measure, is also recommended by IMMPACT, and was included as a secondary outcome measure (<LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-09-18 14:18:29 +1000" MODIFIED_BY="[Empty name]">
<P>1. Efficacy: patient reported pain relief of 30% or greater.</P>
<P>2. Safety: number of withdrawals due to adverse events.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-09-18 15:33:56 +1000" MODIFIED_BY="[Empty name]">
<P>3. Pain:</P>
<P>a. patient reported pain relief of 50% or greater;</P>
<P>b. patient reported global impression of clinical change (PGIC) much or very much improved;</P>
<P>c. proportion of patients achieving pain score below 30/100 mm on a visual analogue scale (VAS);</P>
<P>d. mean change in pain score on a visual analogue scale or numerical rating scale.</P>
<P>4. Number and type of adverse events (AEs) and serious adverse events (SAEs, defined as AEs that are fatal, life-threatening, or require hospitalization).</P>
<P>5. Function, as measured by the Health Assessment Questionnaire (HAQ) or modified HAQ (<LINK REF="REF-Fries-1980" TYPE="REFERENCE">Fries 1980</LINK>; <LINK REF="REF-Pincus-1983" TYPE="REFERENCE">Pincus 1983</LINK>).</P>
<P>6. Quality of life, as measured by either generic instruments (such as the Short Form-36 (SF-36)) or disease-specific tools (such as the Rheumatoid Arthritis Quality of Life instrument (RAQoL)).</P>
<P>7. Participant withdrawals due to inadequate analgesia.</P>
<P>The duration of trials of interventions for pain varies considerably. The efficacy of interventions, and the relative balance of benefits and harms, may vary according to the duration of the trial and therefore the combination of results from trials of different durations may represent a source of bias in systematic reviews (<LINK REF="REF-Moore-2010a" TYPE="REFERENCE">Moore 2010a</LINK>). For the purpose of this review, trials were grouped into those of duration &lt; one week, one to six weeks, and &gt; six weeks.</P>
<P>A summary of findings table was generated that included the following outcomes of importance to patients: the proportion of patients reporting a PGIC of 'good' or 'very good', the number of withdrawals due to inadequate analgesia, function, the number of participants reporting adverse events, total number of withdrawals due to adverse effects, and number of serious adverse events.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-09-18 14:26:05 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2011-09-17 22:57:34 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the following databases for RCTs or CCTs using the search strategies detailed in the appendices.</P>
<P>1. Ovid MEDLINE (1950 to May 2010) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<P>2. EMBASE (1980 to May 2010) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<P>3. Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library </I>(<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
<P>No language restrictions were applied.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-09-18 14:26:05 +1000" MODIFIED_BY="[Empty name]">
<P>Abstracts from the two major international rheumatology scientific meetings, the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR), were also searched for the years 2008 and 2009.</P>
<P>The reference lists of included articles were inspected for additional trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-09-18 14:48:50 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-09-18 14:26:36 +1000" MODIFIED_BY="[Empty name]">
<P>All identified studies were assessed independently by two review authors (SW, BR) to identify the trials that fulfilled the inclusion criteria. All possibly relevant articles were retrieved in full text and any disagreement in study selection was resolved by consensus or by discussion with a third review author (RB or EH), as needed. Studies were translated into English where necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-09-18 14:27:57 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (SW and BR) independently extracted relevant information from the included trials including study design, characteristics of the study population, treatment regimen and duration, outcomes and timing of outcome assessment using predetermined forms. The raw data (means and standard deviations for continuous outcomes and number of events or participants for dichotomous outcomes) were extracted for the outcomes of interest.</P>
<P>Differences in the data extracted were resolved by referring back to the original articles and establishing consensus. A third review author (RB or EH) was consulted to help resolve differences, if necessary.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-09-18 14:30:09 +1000" MODIFIED_BY="[Empty name]">
<P>The potential for bias in the included studies was assessed using a risk of bias table. Two authors (SW, BR) independently assessed risk of bias for all included studies for the following items: random sequence generation; allocation concealment; blinding of participants, care provider, and outcome assessor for each outcome measure (see primary and secondary outcome measures); incomplete outcome data and other biases. This conformed to the methods recommended by The Cochrane Collaboration (<LINK REF="REF-Higgins-2009a" TYPE="REFERENCE">Higgins 2009a</LINK>). To determine the risk of bias of a study, for each criterion the presence of sufficient information and the likelihood of potential bias was evaluated. Each criterion was rated as 'Yes' (low risk of bias), 'No' (high risk of bias) or 'Unclear' (either lack of information or uncertainty over the potential for bias). In a consensus meeting disagreements among the authors were discussed and resolved. A third review author (RB or EH) was available to make the final decision if no consensus had been reached but was not required.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-09-18 14:33:56 +1000" MODIFIED_BY="[Empty name]">
<P>The data were summarized in a meta-analysis only if there was sufficient clinical and statistical homogeneity. For continuous data, results were analysed as mean differences between the intervention and comparator group (MD), with corresponding 95% confidence intervals (CI). The mean difference between the treated group and the control group was weighted by the inverse of the variance in the pooled treatment estimate. For dichotomous data, a relative risk (RR) with corresponding 95% CI was calculated. Where dichotomous data from cross-over trials were combined with data from parallel-group trials using the generic inverse variance methods, the odds ratio (OR) with 95% CI was calculated rather than the RR.</P>
<P>For studies containing more than two intervention groups, when making multiple pair-wise comparisons between all possible pairs of intervention groups possible we planned to include the same group of participants only once in the meta-analysis.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-09-18 14:35:11 +1000" MODIFIED_BY="[Empty name]">
<P>In the event that cross-over trials were identified in which the reporting of continuous outcome data precluded paired analysis, these data were not included in a meta-analysis in order to avoid unit-of-analysis error. Where carry-over effects were thought to exist, and where sufficient data existed, data from the first period only were included in the analysis (<LINK REF="REF-Higgins-2009b" TYPE="REFERENCE">Higgins 2009b</LINK>). Where dichotomous data from cross-over trials could be adequately extracted, a paired analysis (McNemar's test) was used to estimate the treatment effect (OR) and the corresponding standard error. Where appropriate, ORs from cross-over trials may be included in a meta-analysis with data from parallel-group trials using the generic inverse variance method; in all such cases a sensitivity analysis was performed that excluded data from cross-over trials (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). McNemar's test was performed using Stata v9.2.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-09-18 14:39:15 +1000" MODIFIED_BY="[Empty name]">
<P>Where important data were missing or incomplete, we planned to seek further information from the study authors, however this was not required for this review.</P>
<P>In cases where individuals were missing from the reported results, we assumed the missing values to have a poor outcome. For dichotomous outcomes that measured adverse events (for example number of withdrawals due to adverse events), the withdrawal rate was calculated using the number of patients that received treatment as the denominator (worst case analysis). For dichotomous outcomes that measured benefits (for example proportion of participants achieving an ACR20 response), we used the worst case analysis by using the number of randomized participants as the denominator. For continuous outcomes (for example pain), we calculated the MD or standardised mean difference (SMD) based on the number of patients analysed at the time point. If the number of patients analysed was not presented for each time point, the number of randomized patients in each group at baseline was to be used.</P>
<P>Where possible, missing standard deviations were computed from other statistics such as standard errors, CIs or P values according to the methods recommended in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2009c" TYPE="REFERENCE">Higgins 2009c</LINK>). If standard deviations could not be calculated, they were imputed (for example from other studies in the meta-analysis) (<LINK REF="REF-Higgins-2009b" TYPE="REFERENCE">Higgins 2009b</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-09-18 14:41:17 +1000" MODIFIED_BY="[Empty name]">
<P>Prior to meta-analysis, we assessed studies for clinical homogeneity with respect to type of therapy, control group, and the outcomes. For any studies judged as clinically homogeneous, statistical heterogeneity was assessed using the I<SUP>2 </SUP>statistic (<LINK REF="REF-Deeks-2009" TYPE="REFERENCE">Deeks 2009</LINK>) and using the following as a rough guide for interpretation: 0% to 40% might not be important heterogeneity, 30% to 60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity and 75% to 100% considerable heterogeneity. In cases of considerable heterogeneity (defined as I<SUP>2 </SUP>&#8805; 75%), we planned to explore the data further, including subgroup analyses, in an attempt to explain the heterogeneity; however statistical heterogeneity of this magnitude was not found in any of our meta-analyses.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-09-18 14:44:25 +1000" MODIFIED_BY="[Empty name]">
<P>In order to determine whether reporting bias was present, we determined whether the protocol of the RCT was published before recruitment of the patients was started. For studies published after July 1st 2005, we screened the Clinical Trial Register at the International Clinical Trials Registry Platform of the World Health Organization (http://apps.who.int/trialsearch) (<LINK REF="REF-DeAngelis-2004" TYPE="REFERENCE">DeAngelis 2004</LINK>). We evaluated whether selective reporting of outcomes was present (outcome reporting bias).</P>
<P>We compared the fixed-effect model estimate against the random-effects model to assess the possible presence of small sample bias in the published literature (that is where the intervention effect is more beneficial in smaller studies). In the presence of small sample bias, the random-effects model estimate of the intervention is more beneficial than the fixed-effect model estimate (<LINK REF="REF-Sterne-2008" TYPE="REFERENCE">Sterne 2008</LINK>).</P>
<P>The potential for reporting bias was to be further explored by funnel plots if &#8805;10 studies were available, however the heterogeneity of outcomes in the included studies precluded this form of analysis.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-09-18 14:44:43 +1000" MODIFIED_BY="[Empty name]">
<P>Where studies were sufficiently homogeneous that it remained clinically meaningful for them to be pooled, meta-analysis was performed using a random-effects model regardless of the I<SUP>2 </SUP>statistic results. Analysis was performed using Review Manager 5 and forest plots were produced for all analyses.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-09-17 23:06:31 +1000" MODIFIED_BY="[Empty name]">
<P>Where sufficient data were available, the following subgroup analyses were planned:</P>
<P>1. patients' age (&lt; 65 years versus &#8805; 65 years);</P>
<P>2. opioid formulation (short-acting versus sustained-release);</P>
<P>3. route of opioid administration (oral versus parenteral);</P>
<P>4. duration of RA (&#8804; 2 years versus &gt; 2 years).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-09-18 14:48:50 +1000" MODIFIED_BY="[Empty name]">
<P>Where sufficient studies existed, sensitivity analyses were planned to assess the impact of any bias attributable to inadequate or unclear treatment allocation (including studies with quasi-randomized designs).</P>
<SUBSECTION>
<HEADING LEVEL="4">Presentation of key results</HEADING>
<P>A summary of findings table was produced using GRADEpro software. This table provides key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes (short and long-term outcomes for pain and function, the total number of adverse events, serious adverse events and withdrawals due to adverse effects) as recommended by The Cochrane Collaboration (<LINK REF="REF-Sch_x00fc_nemann-2008a" TYPE="REFERENCE">Schünemann 2008a</LINK>). It includes an overall grading of the evidence related to each of the main outcomes using the GRADE approach (<LINK REF="REF-Sch_x00fc_nemann-2008b" TYPE="REFERENCE">Schünemann 2008b</LINK>).</P>
<P>In addition to the absolute and relative magnitude of effect provided in the summary of findings table, for dichotomous outcomes the number needed to treat to benefit (NNTB) or the number needed to treat to harm (NNTH) was calculated, where appropriate. from the control group event rate (unless the population event rate was known) and the relative risk (RR) using the Visual Rx NNT calculator (<LINK REF="REF-Cates-2004" TYPE="REFERENCE">Cates 2004</LINK>).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-09-18 15:33:24 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-09-18 15:01:39 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>Thirty-three possibly eligible studies were identified. Twenty-two studies were excluded; the reasons for exclusion are listed in the table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'.</P>
<P>Eleven studies (672 participants), published between 1969 and 2006, were included in the review (see flow chart in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). A full description of the included studies is provided in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. Ten of the included studies were published in English and one (<LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>) was published in German. Two further non-English studies (<LINK REF="STD-Tadashi-1972" TYPE="STUDY">Tadashi 1972</LINK> in Japanese, <LINK REF="STD-Pavelka-1984" TYPE="STUDY">Pavelka 1984</LINK> in Czech) were potentially eligible for inclusion based on their titles but were awaiting translation at the time of publication of this review. The review will be updated to include data from these studies if they are found to meet inclusion criteria.</P>
<P>Nine studies were published prior to 2000. One study was conducted in the USA (<LINK REF="STD-Hardin-1979" TYPE="STUDY">Hardin 1979</LINK>), one in Korea (<LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>) and the remainder in the United Kingdom or Europe. One study (<LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>) included 277 participants; the number of participants in the other 10 studies ranged from 16 to 78. Seven of the included studies used a cross-over design (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>; <LINK REF="STD-Hardin-1979" TYPE="STUDY">Hardin 1979</LINK>; <LINK REF="STD-Hill-1970" TYPE="STUDY">Hill 1970</LINK>; <LINK REF="STD-Huskisson-1974" TYPE="STUDY">Huskisson 1974</LINK>; <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>; <LINK REF="STD-Saarialho-1988" TYPE="STUDY">Saarialho 1988</LINK>) and the other four studies used a parallel-group design (<LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>). In one of the cross-over studies (<LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>) only four of the 20 participants completed both phases of the trial so efficacy data were reported for the first phase only and this could be considered as a parallel-design trial for the purpose of analysis.</P>
<P>All included studies recruited adult participants. Five studies (<LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>) reported the mean age of participants, which ranged from 52 to 58 years. The age range of participants was 21 to 79 years in the four studies (<LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>; <LINK REF="STD-Saarialho-1988" TYPE="STUDY">Saarialho 1988</LINK>) where the range was reported. Four studies (<LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>; <LINK REF="STD-Saarialho-1988" TYPE="STUDY">Saarialho 1988</LINK>) reported the mean duration of RA in participants, which ranged from 6.2 to 8.8 years. In general, the degree of RA disease activity of participants was not reported. Only <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK> reported the mean C-reactive protein (CRP) measurement at baseline (17mg/L). The proportion of participants receiving background NSAID therapy was not consistently described but, where reported, ranged from 63% (<LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>) to 100% (<LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>; <LINK REF="STD-Saarialho-1988" TYPE="STUDY">Saarialho 1988</LINK>) of participants. Stable background therapy with NSAIDs was permitted to continue in all included studies except for three in which one of the study drugs was an NSAID (<LINK REF="STD-Hardin-1979" TYPE="STUDY">Hardin 1979</LINK>; <LINK REF="STD-Hill-1970" TYPE="STUDY">Hill 1970</LINK>; <LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>). The use of background DMARDs by participants reflected the secular trends in RA management during this period. The use of DMARDs was excluded in only one study, published in 1973 (<LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>). Stable DMARD therapy was permitted to continue in six studies (<LINK REF="STD-Hardin-1979" TYPE="STUDY">Hardin 1979</LINK>; <LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>; <LINK REF="STD-Saarialho-1988" TYPE="STUDY">Saarialho 1988</LINK>). The proportion of participants using DMARDs was reported in only two studies: 88% (<LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>) and 94% (<LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>). In the remaining four studies (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>; <LINK REF="STD-Hill-1970" TYPE="STUDY">Hill 1970</LINK>; <LINK REF="STD-Huskisson-1974" TYPE="STUDY">Huskisson 1974</LINK>; <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>) DMARD use was not reported. None of the participants in the included studies were receiving biologic anti-rheumatic therapy.</P>
<P>Three of the included studies were shorter than a week in duration (<LINK REF="STD-Hardin-1979" TYPE="STUDY">Hardin 1979</LINK>; <LINK REF="STD-Hill-1970" TYPE="STUDY">Hill 1970</LINK>; <LINK REF="STD-Huskisson-1974" TYPE="STUDY">Huskisson 1974</LINK>). All were designed as cross-over trials with sequential administration of multiple interventions, including placebo and non-opioid analgesic drugs in addition to opioids. Each participant received one dose of each intervention in a randomized sequence. A fourth study (<LINK REF="STD-Saarialho-1988" TYPE="STUDY">Saarialho 1988</LINK>) also studied multiple analgesics in sequence. This study was designed to investigate psychomotor responses to analgesic agents in RA but also recorded pain as a secondary outcome. Each of the following four agents were administered to each participant for three days at two-week intervals: indomethacin, dextropropoxyphene, dextropropoxyphene plus amitriptyline, and placebo. Data from these four studies were not included in the meta-analysis.</P>
<P>There were seven studies in which the study drug was administered for at least one week (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>; <LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>; <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>) but there were no studies identified with a follow-up period of longer than six weeks. Six of the seven studies (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>; <LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>; <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>) were placebo-controlled and one (<LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>) compared a codeine-paracetamol compound plus low-dose diclofenac with standard-dose diclofenac alone. Four of the seven studies (<LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>) used a parallel-group design; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK> and <LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK> were cross-over trials and <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK> was designed as a cross-over trial but reported the results of the first phase as a parallel-group trial due to an unexpectedly high rate of participant withdrawals. Six different opioids were investigated in the seven studies, most in combination with another non-opioid analgesic: a codeine and paracetamol combination was studied in both <LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK> and <LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>; and the other five studies (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>; <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>) investigated tilidine with naloxone, tramadol with paracetamol, pentazocine, morphine sulphate and dextropropoxyphene respectively. Morphine (<LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>) was the only strong opioid investigated in the 11 included studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-09-18 15:03:59 +1000" MODIFIED_BY="[Empty name]">
<P>The results of the risk of bias assessment are presented in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<P>Sequence generation and allocation concealment were insufficiently described for a clear judgement regarding bias in the majority of studies, and there was a high risk of biased randomization in at least two studies. Only <LINK REF="STD-Hardin-1979" TYPE="STUDY">Hardin 1979</LINK> clearly described an adequate method of allocation concealment. While most studies used a matching placebo, and all 11 studies were described as 'double-blind', it was often unclear whether all of the study personnel were blinded to treatment allocation. Three of the studies that were at least one week in duration excluded drop-outs from the data analysis (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>; <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>). Of the four sequential single-dose studies, one (<LINK REF="STD-Huskisson-1974" TYPE="STUDY">Huskisson 1974</LINK>) presented data for fewer participants than had been randomized, but no description of drop-outs was provided; and in two (<LINK REF="STD-Hardin-1979" TYPE="STUDY">Hardin 1979</LINK>, <LINK REF="STD-Hill-1970" TYPE="STUDY">Hill 1970</LINK>) data were presented only for those who completed the study and the number of drop-outs was not provided. There was a high risk of outcome reporting bias in five of the included studies (<LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>; <LINK REF="STD-Hill-1970" TYPE="STUDY">Hill 1970</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-09-18 15:33:24 +1000" MODIFIED_BY="[Empty name]">
<P>Due to differences in study duration and design, the seven studies that were at least one week in duration (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>; <LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>; <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>) were considered separately from the four trials that evaluated single doses of different analgesic drugs in sequence (<LINK REF="STD-Hardin-1979" TYPE="STUDY">Hardin 1979</LINK>; <LINK REF="STD-Hill-1970" TYPE="STUDY">Hill 1970</LINK>; <LINK REF="STD-Huskisson-1974" TYPE="STUDY">Huskisson 1974</LINK>; <LINK REF="STD-Saarialho-1988" TYPE="STUDY">Saarialho 1988</LINK>). Due to heterogeneity in study design and outcome measures in the latter four trials, a pooled analysis was not performed for these studies, which are instead described below.</P>
<P>Participants in <LINK REF="STD-Hardin-1979" TYPE="STUDY">Hardin 1979</LINK> received analgesic-dose aspirin (650 mg), paracetamol, codeine sulphate, propoxyphene, pentazocine and placebo on consecutive days.The authors reported that single doses of all of the active agents resulted in superior pain relief compared to placebo. There were no significant differences in total pain relief between the active agents, although a significantly smaller proportion of those treated with propoxyphene achieved at least 50% reduction in pain compared with those treated with aspirin. <LINK REF="STD-Hill-1970" TYPE="STUDY">Hill 1970</LINK> compared single doses of a compound of codeine phosphate, phenacetin and acetylsalicylic acid; two different doses of a compound of caffeine, phenacetin and isopropylantipyrine; and placebo administered sequentially on consecutive days. Pain relief was similar among the active treatments and all were superior to placebo. The study by <LINK REF="STD-Huskisson-1974" TYPE="STUDY">Huskisson 1974</LINK> comprised three separate trials that each evaluated single doses of several analgesic drugs plus placebo. The study drugs included the opioids pentazocine, codeine (in combination with aspirin), dextropropoxyphene (in combination with paracetamol) and an experimental agent structurally related to propoxyphene (Ciba 44,328). Non-opioid study drugs included paracetamol and aspirin. All of the active treatments were associated with superior pain relief compared with placebo, but there was no consistent difference in efficacy between the active drugs. The primary outcome in the study by <LINK REF="STD-Saarialho-1988" TYPE="STUDY">Saarialho 1988</LINK> was psychomotor performance in RA patients after treatment with analgesic medications, but pain scores were also recorded. Dextropropoxyphene at a dose of 130 mg had a greater effect on pain than either placebo or dextropropoxyphene 65 mg combined with amitriptyline 25 mg.</P>
<SUBSECTION>
<HEADING LEVEL="4">Opioid versus placebo</HEADING>
<P>Six studies, with a total of 448 participants, had a duration of at least one week and investigated the effectiveness of opioids versus placebo (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>; <LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>; <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>). The longest study (<LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>) was six weeks in duration. One study (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>) compared the combination of dextropropoxyphene and aspirin with aspirin alone; the remainder compared an opioid with a matching placebo. In all six studies, participants who had been taking stable doses of NSAIDs were permitted to continue the background drug during the trial. Each of the six studies evaluated a different opioid and only one, morphine sulphate in <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>, was considered as a strong opioid. The active intervention in three of the six studies was an opioid in combination with a non-opioid analgesic: codeine plus paracetamol (<LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>), tramadol plus paracetamol (<LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>), and dextropropoxyphene plus aspirin (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>). The active intervention in <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK> was tilidine in combination with naloxone, and in the remaining two studies the active intervention was an opioid alone: pentazocine in <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK> and morphine sulphate in <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Efficacy outcomes</HEADING>
<P>Five of the six studies reported superiority of the study drug compared with placebo on at least one efficacy measure (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>; <LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>; <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>); no difference between pentazocine and placebo was found for any efficacy measure in <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>. None of the six studies reported the primary outcome measure of patient reported pain relief of 30% or greater. <LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK> reported the proportion of participants achieving pain relief of 50% or greater in a seven-day trial of codeine and paracetamol versus placebo in patients with at least moderate pain due to RA: 12 of 20 (60%) participants who received the active drug achieved this outcome compared with 5 of 19 (26%) who received placebo (RR 2.28, 95% CI 0.99 to 5.25). There were insufficient continuous pain data in these six studies for a pooled analysis.</P>
<P>Comparable measures of patient reported global impression of clinical change could be extracted from three studies (324 participants). <LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK> and <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK> reported the proportion of participants with self-reported global efficacy of 'good' or 'very good' and <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK> reported the proportion of participants who were 'improved' versus 'not improved' or 'worse'. Although three different weak oral opioids were used in these studies (codeine with paracetamol, tramadol with paracetamol, tilidine with naloxone, respectively), the age and gender of participants, disease duration and background DMARD and NSAID use in each of the studies were sufficiently homogeneous to allow a meaningful pooling of results. The pooled analysis demonstrated opioids to be superior to placebo (RR 1.44, 95% CI 1.03 to 2.03). The estimated NNT for one extra patient to achieve a benefit rated as 'good' or 'very good' within the first six weeks was 6 (95% CI 3 to 84). An I<SUP>2 </SUP>of 16% indicated a low degree of heterogeneity between trials.</P>
<P>Four studies with 345 participants (<LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>; <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK>) assessed the number of withdrawals due to inadequate analgesia. There was no significant difference between the opioid and placebo groups (RR 0.82, 95% CI 0.34 to 2.01). There was no statistical evidence for heterogeneity in the included trials (I<SUP>2 </SUP>= 0%).</P>
<P>Three studies assessed function. <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK> and <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK> measured the HAQ score at one week and two weeks, respectively. Neither study found a significant difference between groups, nor was there a difference in the pooled analysis (weighted MD -0.10, 95% CI -0.33 to 0.13). <LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK> used a self-reported disability scale (none, mild, moderate, severe) measured daily for seven days and found codeine plus paracetamol to be superior to placebo (repeated measures ANOVA, P = 0.04).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Safety outcomes</HEADING>
<P>Data on the proportion of participants who experienced at least one adverse event could be pooled for four studies (three parallel-group design, one cross-over study) with a total of 371 participants (<LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>; <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>). Almost half (47.7%) of participants reported at least one adverse event, and the risk was significantly higher for those who received an opioid versus placebo (OR 3.90, 95% CI 2.31 to 6.56; I<SUP>2 </SUP>= 0%). This equates to an estimated NNT with opioids to result in one additional adverse event within the first six weeks of opioid therapy of 4 (95% CI 3 to 6). A sensitivity analysis that excluded the cross-over study (<LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK>) was performed but the results were similar (OR 3.85, 95% CI 2.23 to 6.67). Adverse effects resulted in withdrawal from the trial for 14.8% of participants in the three parallel-group trials. The rate of withdrawal was higher for those who received an opioid, although the difference was not statistically significant (3 studies, 331 participants: RR 2.67, 95% CI 0.52 to 13.75). An I<SUP>2 </SUP>of 57% indicated a moderate degree of heterogeneity between trials for this outcome.</P>
<P>Data for withdrawals due to adverse events from the <LINK REF="STD-Nuki-1973" TYPE="STUDY">Nuki 1973</LINK> study could not be pooled, however adverse effects resulted in discontinuation of treatment in 3/35 participants during the pentazocine phase and 1/35 during the placebo phase. Another cross-over study (<LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>) reported no significant difference in adverse event frequency during treatment with aspirin alone or dextropropoxyphene plus aspirin, although 3/51 participants discontinued treatment due to adverse effects all during the combination therapy phase. <LINK REF="STD-Moran-1991" TYPE="STUDY">Moran 1991</LINK> was the only study to use a strong opioid (controlled-release morphine sulphate). Adverse event data were not presented in a format that was suitable for meta-analysis but only 4/20 participants completed the trial: 11 participants withdrew during the first 4-week phase, 7 of whom were in the morphine group, and a further 5 participants withdrew in the second phase, 3 of whom were receiving morphine. Six of the 10 withdrawals during treatment with morphine were due to adverse effects compared with three of the six withdrawals during placebo treatment.</P>
<P>The most commonly-reported adverse events in the 11 included studies were nausea and vomiting, dizziness or lightheadedness, and constipation. These data were insufficiently reported for a pooled analysis. One of the single-dose studies (<LINK REF="STD-Huskisson-1974" TYPE="STUDY">Huskisson 1974</LINK>) did not report any data on adverse events. Two serious adverse events (SAEs) were reported, one from each of two studies, although <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK> was the only study to specify SAEs as an outcome measure. One participant in <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>, in the tramadol plus paracetamol group, experienced chest pain, nausea and vomiting that were sufficiently severe to be classified as an SAE; the symptoms resolved within a day of discontinuation of the study drug. One participant in <LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>, who was receiving dextropropoxyphene plus aspirin, developed haematemesis and melaena and was described as having an existing duodenal ulcer. The patient was withdrawn from the trial and no further details regarding the adverse event were given.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Risk versus benefit</HEADING>
<P>In order to combine an estimate of both the benefits and harms of opioid therapy in RA into a single measure, a Net Efficacy Adjusted for Risk (NEAR) analysis was performed (<LINK REF="REF-Boada-2008" TYPE="REFERENCE">Boada 2008</LINK>). This method estimates the RR of simultaneously achieving a benefit and avoiding harm in study participants treated with opioid versus placebo since this state, a clinical benefit without a significant adverse drug reaction, is the optimal outcome in patients who require analgesic medications. For this analysis, a patient global impression of change of 'good' or 'very good' was chosen as the efficacy outcome, and adverse effects sufficient to warrant discontinuation of the drug were chosen as the most relevant measure of harm. Data for this analysis could be extracted from three studies (<LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>), which included 324 participants. The NEAR RR (that is the risk of achieving benefit without harm for those treated with opioids versus placebo) was 1.20 (95% CI 0.89 to 1.61); therefore, by this measure, opioids were not superior to placebo. See <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Opioid versus NSAID</HEADING>
<P>One study (<LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>) with 60 participants compared opioid therapy with an NSAID. This one-week trial randomized participants on stable background therapy for RA to treatment with diclofenac 50 mg twice daily or one tablet of codeine 30 mg with paracetamol 500 mg three times daily plus diclofenac 50 mg at night. No difference was found between treatment groups in either efficacy outcomes (change in pain VAS, patient global impression, disability) or adverse effects.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-09-18 15:50:48 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-09-18 15:39:35 +1000" MODIFIED_BY="[Empty name]">
<P>None of the 11 included studies reported the primary efficacy outcome of this review, patient reported pain relief of 30% or greater, and the secondary efficacy outcomes were variably reported. Four of the studies investigated the effectiveness of single doses of opioids; of the remaining seven studies the median duration was one week and the longest follow-up period was only six weeks. In general, the risk of bias in the included studies was high as the method by which treatment assignment was randomized and concealed was poorly reported, and participants with missing data were often excluded from analysis even in studies claiming to have performed an intention-to-treat analysis. The single-dose studies all reported superior pain relief with opioids compared with placebo but did not show superiority to non-opioid analgesics. Of the six studies that compared regular opioid therapy with placebo, five demonstrated superiority of opioids on at least one efficacy measure. No difference between treatments was found in the one study that compared an opioid with an NSAID.</P>
<P>Dichotomous responder outcomes have been suggested to be the preferred outcome measures in pain trials due to the difficulty in interpreting the clinical relevance of group means for continuous outcomes when the underlying distribution is often skewed (<LINK REF="REF-Moore-2010a" TYPE="REFERENCE">Moore 2010a</LINK>). Of the three dichotomous secondary outcome measures for efficacy planned for this review, none of the included studies reported the proportion of patients achieving a pain score below 30/100 mm on a visual analogue scale, and only one (<LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>) reported patient reported pain relief of 50% or greater. The third, patient reported global impression of clinical change (PGIC) 'much' or 'very much' improved, or a comparable patient-reported global measure, was reported by three studies (<LINK REF="STD-Boureau-1991" TYPE="STUDY">Boureau 1991</LINK>; <LINK REF="STD-Brunnmuller-2004" TYPE="STUDY">Brunnmuller 2004</LINK>; <LINK REF="STD-Lee-2006" TYPE="STUDY">Lee 2006</LINK>) and on pooled analysis opioids were found to be superior to placebo. Four studies reported the number of participant withdrawals due to inadequate analgesia; no difference between opioid and placebo was found for this outcome in any of the studies or on pooled analysis.</P>
<P>Only two studies reported functional outcomes and in neither case was there a difference between opioids and placebo. None of the included studies reported quality of life data.</P>
<P>Despite the short duration of the included studies, approximately half of the participants who received an opioid reported at least one adverse event, and for one in six of these participants the adverse effects were sufficient to cause withdrawal from the study. Adverse events were more frequent among those treated with opioids in all of the placebo-controlled studies that were at least one week in duration, and pooled analysis found a four-fold increase in the odds of adverse events in opioid-treated patients. No difference in the incidence of adverse events was found in <LINK REF="STD-Bedi-1969" TYPE="STUDY">Bedi 1969</LINK>, a cross-over trial of dextropropoxyphene and aspirin versus aspirin alone, and <LINK REF="STD-Glowinski-1999" TYPE="STUDY">Glowinski 1999</LINK>, the only trial to directly compare an opioid with an NSAID. Only two serious adverse events were reported and there were no deaths. Where reported, the adverse events appeared to be relatively mild and were consistent with recognized opioid adverse effects, including nausea, vomiting, constipation and dizziness. A pooled analysis of withdrawals due to adverse effects in the placebo-controlled trials also suggested an increased risk in opioid-treated participants, although this difference was not statistically significant. After adjustment for adverse effects (the net efficacy adjusted for risk analysis), the superiority of opioids in achieving a PGIC of 'good' or 'very good' was no longer statistically significant suggesting that in patients with RA who are treated with opioids for up to six weeks, the analgesic benefits may be offset by adverse effects.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-09-18 15:45:13 +1000" MODIFIED_BY="[Empty name]">
<P>The overall balance of benefits and harms associated with opioid use is a key issue for RA sufferers and the medical practitioners who care for them. RA is a chronic disease and analgesic medications may be required both in the short term (for example during flares of inflammatory activity or while waiting for DMARDs to take effect) and in the long term (for example due to irreversible joint damage or the development of secondary central pain syndromes such as fibromyalgia). It is not necessarily the case that the efficacy or safety of opioids, or the balance between the two, is similar for short-term versus long-term use or for pain of different mechanistic origin. The studies in this review were performed between 1969 and 2006, an era that has seen revolutionary changes in the management of the inflammatory component of RA. While none of the included studies attempted to describe the nature of the pain suffered by the participants, it is quite likely that pain of an inflammatory nature was more prominent in the earlier studies than those performed in the last decade. Although RA disease activity was not reported in the included studies, and DMARD use was incompletely reported, the use of DMARDs by participants in the included studies tended to be more prevalent in the latter studies. None of the participants were receiving biologic therapy. The significant changes in the management of RA that have occurred in the years covered by the studies in this review may limit the applicability of the results to RA patients in the current era, however pain remains a significant management challenge in RA today and the review highlights the need for further well-designed pain research in RA patients who are receiving modern disease-modifying treatment strategies.</P>
<P>For RA patients who experience persistent pain despite optimal control of synovial inflammation, there may be a long-term requirement for analgesic medications. There is a relative paucity of evidence regarding the risk-benefit profile of opioid analgesics in this population and in the longer term (<LINK REF="REF-Furlan-2006" TYPE="REFERENCE">Furlan 2006</LINK>). Some unwanted effects, such as endocrinopathy and opioid-induced hyperalgesia, may increase in prevalence with chronic use, while tolerance to other adverse effects may develop (<LINK REF="REF-Chu-2008" TYPE="REFERENCE">Chu 2008</LINK>; <LINK REF="REF-Rhodin-2010" TYPE="REFERENCE">Rhodin 2010</LINK>). The risk of opioid addiction among long-term users is also a concern for many prescribers.</P>
<P>A Cochrane review of long-term opioid use (at least six months) for chronic non-cancer pain (<LINK REF="REF-Noble-2010" TYPE="REFERENCE">Noble 2010</LINK>) found the rate of withdrawal due to adverse effects to be 11.4% (95% CI 7.0% to 8.1%) for weak oral opioids and 34.1% (95% CI 29.2% to 39.3%) for strong oral opioids. The rate of addiction or abuse was estimated at 0.27%. Clinically-relevant analgesia was achieved with oral opioids, however the included studies were predominantly uncontrolled and reliable effect sizes could not be estimated. Although none of the studies included in that review involved participants with RA, the conclusions are likely to be applicable to the RA population. High-quality trials of long-term opioid use in the setting of inflammatory arthritis and other non-malignant chronic pain states are clearly required.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-09-18 15:47:30 +1000" MODIFIED_BY="[Empty name]">
<P>The 11 studies included in this review were heterogeneous with regard to the opioid studied, the concurrent use of non-opioid analgesics, the outcomes measured, the background disease-modifying anti-rheumatic therapy and the era in which the study was performed; and the risk of bias was generally high. In light of this, the quantitative findings of this review must be interpreted with great caution. At best, there is weak evidence in favour of the efficacy of opioids for the treatment of pain in patients with RA but, as no study was longer than six weeks in duration, no reliable conclusions can be drawn regarding the efficacy or safety of opioids in the longer term.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-09-18 15:48:24 +1000" MODIFIED_BY="[Empty name]">
<P>We believe that all relevant studies were identified. A thorough search strategy was devised and all major databases were searched for relevant studies with no language restrictions applied. Two review authors assessed the trials for inclusion in the review and risk of bias, with a third review author adjudicating when there was any discrepancy. The biggest limitation of the review process was that many trials did not provide enough published data, or data in a form that could be extracted for meta-analysis.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-09-18 15:50:48 +1000" MODIFIED_BY="[Empty name]">
<P>No previous reviews of opioids in RA were identified. Findings from systematic reviews of opioid therapy in other chronic painful musculoskeletal syndromes may be informative, however. A Cochrane review of the treatment of chronic non-cancer pain with at least six months of opioid therapy (<LINK REF="REF-Noble-2010" TYPE="REFERENCE">Noble 2010</LINK>), discussed above, did not include any studies of RA but did include other painful musculoskeletal conditions, such as osteoarthritis and back pain. The conclusions were similar, that a proportion of patients with chronic non-malignant pain who are treated with opioids achieve clinically-significant analgesia, but adverse effects are common and limit use in many patients. Similarly, a Cochrane review of oral opioids (including codeine, oxycodone, oxymorphone and morphine) or transdermal fentanyl for osteoarthritis of the knee or hip (<LINK REF="REF-Nuesch-2009" TYPE="REFERENCE">Nuesch 2009</LINK>) found a mild improvement in pain scores with opioids versus control interventions but this was potentially outweighed by an increase in the risk of adverse events (RR 1.55, 95% CI 1.41 to 1.70) or withdrawal due to adverse events (RR 4.05, 95% CI 3.06 to 5.38). The authors concluded that, due to the poor risk-benefit profile, these opioids should not be routinely used for pain due to osteoarthritis of the knee or hip. A systematic review of the prevalence of adverse events in RCTs of opioids for chronic non-malignant pain (including, but not limited to, RA) found a rate of adverse events (approximately one in two participants) and withdrawal due to adverse events (approximately one in five) that were very similar to the findings of our review (<LINK REF="REF-Moore-2005" TYPE="REFERENCE">Moore 2005</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-09-18 15:53:13 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-01-10 16:10:22 +1100" MODIFIED_BY="[Empty name]">
<P>Based on the results of this review, treatment of RA patients with weak oral opioids for up to six weeks may offer clinically-relevant improvement in pain, but adverse effects are common and limit the utility of this class of analgesics. There is insufficient evidence to draw conclusions regarding the regular use of weak oral opioids for longer than six weeks, or the use of strong opioids for any duration. There is no existing evidence in this population that compares different opioids, different routes of delivery, or different dosing regimens.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-09-18 15:53:13 +1000" MODIFIED_BY="[Empty name]">
<P>More evidence regarding the effectiveness and safety of chronic opioid use in patients with RA and other inflammatory rheumatic diseases is required. Future RCTs should be adequately powered and should have follow-up periods of at least six weeks (and preferably 12 weeks or longer), clinically-relevant pain outcomes, rigorous collection of adverse event data, and blinded participants and outcome assessment. Further trials should seek to compare the risk-benefit profiles of different opioids, different routes of administration and combination analgesic strategies. Clinical effectiveness studies (described in <LINK REF="REF-Moore-2010b" TYPE="REFERENCE">Moore 2010b</LINK>) that are structured to more accurately reflect decision-making in real-world management of chronic painful conditions would be of great value. The optimal management of pain in patients with RA remains a critical field of inquiry.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-09-06 17:32:11 +1000" MODIFIED_BY="[Empty name]">
<P>The authors thank Louise Falzon, Trials Search Coordinator of the Cochrane Musculoskeletal Group, for assisting with the design of the search strategy.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-09-17 23:33:32 +1000" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-09-18 15:53:36 +1000" MODIFIED_BY="[Empty name]">
<P>SW wrote the current version of the protocol and wrote the review.</P>
<P>EH wrote the original version of the protocol, which provided a base for the development of the current version.</P>
<P>RB, BR and EH provided comments and suggestions on draft versions of the protocol and review and all authors approved the current version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-09-18 15:54:55 +1000" MODIFIED_BY="[Empty name]">
<P>The protocol specified that short and long-term outcomes for the following outcomes would be included in the summary of findings table: proportion reporting pain relief of 30% or greater, total number of withdrawals due to adverse effects, number of serious adverse events, function and quality of life. As none of the included studies reported data for quality of life or the proportion reporting pain relief of 30% or greater, these outcomes were not included in the summary of findings table. Three additional outcomes (the proportion of patients reporting PGIC of 'good' or 'very good', the number of withdrawals due to inadequate analgesia, and the number of participants reporting adverse events) were reported in several of the included studies and were felt to be of importance to patients. These outcomes have been added to the summary of findings table. No outcomes were measured beyond six weeks, so only short-term outcomes were included in the table.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-09-18 16:25:47 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-09-18 16:18:23 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-09-18 16:16:53 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bedi-1969" MODIFIED="2011-09-17 23:45:02 +1000" MODIFIED_BY="[Empty name]" NAME="Bedi 1969" YEAR="1969">
<REFERENCE MODIFIED="2011-09-17 23:45:02 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Comparison of aspirin and dextropropoxyphene-with-aspirin as analgesics in rheumatoid arthritisClinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:45:02 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bedi SS</AU>
<TI>Comparison of aspirin and dextropropoxyphene-with-aspirin as analgesics in rheumatoid arthritis</TI>
<SO>The British Journal of Clinical Practice</SO>
<YR>1969</YR>
<VL>23</VL>
<NO>10</NO>
<PG>413-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boureau-1991" MODIFIED="2011-09-18 16:09:07 +1000" MODIFIED_BY="[Empty name]" NAME="Boureau 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-09-18 16:09:07 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Placebo-controlled study of the analgesic efficacy of a combination of paracetamol and codeine in rheumatoid arthritis&lt;/p&gt;" NOTES_MODIFIED="2011-09-18 16:09:07 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boureau F, Boccard E</AU>
<TI>Placebo-controlled study of the analgesic efficacy of a combination of paracetamol and codeine in rheumatoid arthritis</TI>
<SO>Acta Therapeutica</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>2</NO>
<PG>123-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brunnmuller-2004" MODIFIED="2011-09-17 23:46:17 +1000" MODIFIED_BY="[Empty name]" NAME="Brunnmuller 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-09-17 23:46:17 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;FebEffective Analgesic Therapy with Tilidine/Naloxone for Patients with Rheumatoid Arthritis. [German]Wirksame Schmerztherapie mit Tilidin/Naloxon Retard bei Patienten mit Rheumatoider Arthritis (RA).&lt;br&gt;English, German&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:46:17 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brunnmuller U, Zeidler H, Alten R, Gromnica-Ihle E</AU>
<TI>Effective analgesic therapy with tilidine/naloxone for patients with rheumatoid arthritis. [German]</TI>
<SO>Aktuelle Rheumatologie</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>1</NO>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glowinski-1999" MODIFIED="2011-09-18 16:16:53 +1000" MODIFIED_BY="[Empty name]" NAME="Glowinski 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-09-18 16:16:53 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Placebo-controlled study of the analgesic efficacy of a paracetamol 500 mg/Codeine 30 mg combination together with low-dose vs high-dose diclofenac in rheumatoid arthritisJournal: Article&lt;/p&gt;" NOTES_MODIFIED="2011-09-18 16:16:53 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glowinski J, Boccard E</AU>
<TI>Placebo-controlled study of the analgesic efficacy of a paracetamol 500 mg/codeine 30 mg combination together with low-dose vs high-dose diclofenac in rheumatoid arthritis</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>3</NO>
<PG>189-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hardin-1979" MODIFIED="2011-09-17 23:46:42 +1000" MODIFIED_BY="[Empty name]" NAME="Hardin 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-09-17 23:46:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Comparative effectiveness of five analgesics for the pain of rheumatoid synovitisClinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:46:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hardin JG, Kirk KA</AU>
<TI>Comparative effectiveness of five analgesics for the pain of rheumatoid synovitis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1979</YR>
<VL>6</VL>
<NO>4</NO>
<PG>405-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-1970" MODIFIED="2011-09-17 23:47:14 +1000" MODIFIED_BY="[Empty name]" NAME="Hill 1970" YEAR="1970">
<REFERENCE MODIFIED="2011-09-17 23:47:14 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;A comparison of codeine compound and &amp;quot;saridone&amp;quot; in the pain of rheumatoid arthritisClinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:47:14 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill RC, Turner P</AU>
<TI>A comparison of codeine compound and "saridone" in the pain of rheumatoid arthritis</TI>
<SO>The British Journal of Clinical Practice</SO>
<YR>1970</YR>
<VL>24</VL>
<NO>1</NO>
<PG>29-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huskisson-1974" MODIFIED="2011-09-17 23:47:49 +1000" MODIFIED_BY="[Empty name]" NAME="Huskisson 1974" YEAR="1974">
<REFERENCE MODIFIED="2011-09-17 23:47:49 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Simple analgesics for arthritisClinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:47:49 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huskisson EC</AU>
<TI>Simple analgesics for arthritis</TI>
<SO>British Medical Journal</SO>
<YR>1974</YR>
<VL>4</VL>
<NO>5938</NO>
<PG>196-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2006" MODIFIED="2011-09-17 23:48:25 +1000" MODIFIED_BY="[Empty name]" NAME="Lee 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-09-17 23:48:25 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trialJournal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:48:25 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee EY, Lee EB, Park BJ, Lee CK, Yoo B, Lim MK, et al</AU>
<TI>Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial</TI>
<SO>Clinical Therapeutics</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>12</NO>
<PG>2052-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moran-1991" MODIFIED="2011-09-17 23:50:08 +1000" MODIFIED_BY="[Empty name]" NAME="Moran 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-09-17 23:50:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moran C</AU>
<TI>MST Continus tablets and pain control in severe rheumatoid arthritis</TI>
<SO>British Journal of Clinical Research</SO>
<YR>1991</YR>
<VL>2</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nuki-1973" MODIFIED="2011-09-17 23:50:50 +1000" MODIFIED_BY="[Empty name]" NAME="Nuki 1973" YEAR="1973">
<REFERENCE MODIFIED="2011-09-17 23:50:50 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Clinical trial of pentazocine in rheumatoid arthritis. Observations on the value of potent analgesics and placebosClinical Trial; Controlled Clinical Trial; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:50:50 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nuki G, Downie WW, Dick WC, Whaley K, Spooner JB, Darby Dowman MA, et al</AU>
<TI>Clinical trial of pentazocine in rheumatoid arthritis. Observations on the value of potent analgesics and placebos</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1973</YR>
<VL>32</VL>
<NO>5</NO>
<PG>436-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saarialho-1988" MODIFIED="2011-09-17 23:49:13 +1000" MODIFIED_BY="[Empty name]" NAME="Saarialho 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-09-17 23:49:13 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Psychomotor performance of patients with rheumatoid arthritis: cross-over comparison of dextropropoxyphene, dextropropoxyphene plus amitriptyline, indomethacin, and placeboClinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:49:13 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saarialho Kere U, Julkunen H, Mattila MJ, Seppälä T</AU>
<TI>Psychomotor performance of patients with rheumatoid arthritis: cross-over comparison of dextropropoxyphene, dextropropoxyphene plus amitriptyline, indomethacin, and placebo</TI>
<SO>Pharmacology &amp; Toxicology</SO>
<YR>1988</YR>
<VL>63</VL>
<NO>4</NO>
<PG>286-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-09-18 16:18:23 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Berliner-2007" MODIFIED="2011-09-17 23:51:12 +1000" MODIFIED_BY="[Empty name]" NAME="Berliner 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-09-17 23:51:12 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;JulImpact of transdermal fentanyl on quality of life in rheumatoid arthritisEnglishEnglish&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:51:12 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berliner MN, Giesecke T, Bornhovd KD</AU>
<TI>Impact of transdermal fentanyl on quality of life in rheumatoid arthritis</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>6</NO>
<PG>530-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boureau-1994" MODIFIED="2011-01-04 15:02:53 +1100" MODIFIED_BY="[Empty name]" NAME="Boureau 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-01-04 14:51:36 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;The analgesic efficacy and safety of a paracetamol-codeine association were studied in 40 patients with residual pain in spite of a balanced specific treatment for their rheumatoid arthritis. [French]Etude controlee versus placebo de l'efficacite antalgique d'une association paracetamol 500 mg codeine 30 mg dans la polyarthrite rhumatoide.&lt;br&gt;French, English&lt;/p&gt;" NOTES_MODIFIED="2011-01-04 14:51:36 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boureau F, Boccard E</AU>
<TI>The analgesic efficacy and safety of a paracetamol-codeine association were studied in 40 patients with residual pain in spite of a balanced specific treatment for their rheumatoid arthritis. [French]</TI>
<SO>Rhumatologie</SO>
<YR>1994</YR>
<VL>46</VL>
<NO>6</NO>
<PG>157-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brooke-1966" MODIFIED="2011-09-18 16:14:13 +1000" MODIFIED_BY="[Empty name]" NAME="Brooke 1966" YEAR="1966">
<REFERENCE MODIFIED="2011-09-18 16:14:13 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;MayThe anti-rheumatic effect of DarvonUnited states&lt;/p&gt;" NOTES_MODIFIED="2011-09-18 16:14:13 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brooke JW, Brooke RD</AU>
<TI>The anti-rheumatic effect of Darvon</TI>
<SO>Western Medicine; the Medical Journal of the West</SO>
<YR>1966</YR>
<VL>7</VL>
<NO>5</NO>
<PG>133-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brooks-1982" MODIFIED="2011-09-17 23:52:18 +1000" MODIFIED_BY="[Empty name]" NAME="Brooks 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-09-17 23:52:18 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Comparative effectiveness of 5 analgesics in patients with rheumatoid arthritis and osteoarthritis&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:52:18 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brooks PM, Dougan MA, Mugford S, Meffin E</AU>
<TI>Comparative effectiveness of 5 analgesics in patients with rheumatoid arthritis and osteoarthritis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1982</YR>
<VL>9</VL>
<NO>5</NO>
<PG>723-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buus-1996" MODIFIED="2011-09-17 23:52:44 +1000" MODIFIED_BY="[Empty name]" NAME="Buus 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-09-17 23:52:44 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Antiinflammatory effect and pain relief of intraarticular morphine versus steroid and placebo in patients with reumatoid arthritis (RA)&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:52:44 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buus A, Jensen MP, Branebjerg PE, Jensen TS, Stengaard Pedersen K</AU>
<TI>Antiinflammatory effect and pain relief of intraarticular morphine versus steroid and placebo in patients with reumatoid arthritis (RA)</TI>
<SO>Scandinavian Journal of Rheumatology. Supplement</SO>
<YR>1996</YR>
<VL>106</VL>
<NO>abstract P25</NO>
<PG>45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buus-1998" MODIFIED="2011-09-18 16:16:12 +1000" MODIFIED_BY="[Empty name]" NAME="Buus 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-09-18 16:16:12 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;The nociceptive effect and pharmacokinetics of morphine and its metabolites M6G adn M3G after intra-articular injeciton into inflamed knee joints in rheumatoid arthritis (RA)&lt;/p&gt;" NOTES_MODIFIED="2011-09-18 16:16:12 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buus N, Christrup LL, Stengaard Pedersen K</AU>
<TI>The nociceptive effect and pharmacokinetics of morphine and its metabolites M6G and M3G after intra-articular injeciton into inflamed knee joints in rheumatoid arthritis (RA)</TI>
<SO>Scandinavian Journal of Rheumatology. Supplement</SO>
<YR>1998</YR>
<VL>108</VL>
<PG>P103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fancourt-1984" MODIFIED="2011-09-17 23:53:18 +1000" MODIFIED_BY="[Empty name]" NAME="Fancourt 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-09-17 23:53:18 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;A double-blind comparison of meptazinol versus placebo in chronic rheumatoid arthritis and osteoarthritisClinical Trial; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:53:18 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fancourt GJ, Flavell Matts SG</AU>
<TI>A double-blind comparison of meptazinol versus placebo in chronic rheumatoid arthritis and osteoarthritis</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1984</YR>
<VL>9</VL>
<NO>3</NO>
<PG>184-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flavell_x002d_Matts-1980" MODIFIED="2011-09-18 16:18:23 +1000" MODIFIED_BY="[Empty name]" NAME="Flavell-Matts 1980" YEAR="1980">
<REFERENCE MODIFIED="2011-09-18 16:18:23 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;OctClinical Trial&lt;br&gt;Comparative Study&lt;br&gt;Randomized Controlled TrialEngland&lt;/p&gt;" NOTES_MODIFIED="2011-09-18 16:18:23 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flavell-Matts SG, Ward PJ</AU>
<TI>A double blind comparison of meptazinol versus pentazocine in chronic rheumatoid and osteoarthritis</TI>
<SO>The British Journal of Clinical Practice</SO>
<YR>1980</YR>
<VL>34</VL>
<NO>10</NO>
<PG>286-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gum-1966" MODIFIED="2011-09-17 23:54:04 +1000" MODIFIED_BY="[Empty name]" NAME="Gum 1966" YEAR="1966">
<REFERENCE MODIFIED="2011-09-17 23:54:04 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;A controlled study of two preparations, paramethasone, propoxyphene, and aspirin and propoxyphene and aspirin in the treatment of arthritisClinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:54:04 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gum OB</AU>
<TI>A controlled study of two preparations, paramethasone, propoxyphene, and aspirin and propoxyphene and aspirin in the treatment of arthritis</TI>
<SO>The American Journal of the Medical Sciences</SO>
<YR>1966</YR>
<VL>251</VL>
<NO>3</NO>
<PG>328-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrero_x002d_Beaumont-2004" MODIFIED="2011-09-17 23:54:45 +1000" MODIFIED_BY="[Empty name]" NAME="Herrero-Beaumont 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-09-17 23:54:45 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;NovClinical Trial&lt;br&gt;Comparative Study&lt;br&gt;Multicenter Study&lt;br&gt;Research Support, Non-U.S. Gov'tGermany&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:54:45 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrero-Beaumont G, Bjorneboe O, Richarz U, Herrero-Beaumont G, Bjorneboe O, Richarz U</AU>
<TI>Transdermal fentanyl for the treatment of pain caused by rheumatoid arthritis</TI>
<SO>Rheumatology International</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>6</NO>
<PG>325-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ingpen-1969" MODIFIED="2011-09-17 23:55:18 +1000" MODIFIED_BY="[Empty name]" NAME="Ingpen 1969" YEAR="1969">
<REFERENCE MODIFIED="2011-09-17 23:55:18 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;A controlled clinical trial of sustained-action dextropropoxyphene hydrochlorideClinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:55:18 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ingpen ML</AU>
<TI>A controlled clinical trial of sustained-action dextropropoxyphene hydrochloride</TI>
<SO>The British Journal of Clinical Practice</SO>
<YR>1969</YR>
<VL>23</VL>
<NO>3</NO>
<PG>113-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maier-2002" MODIFIED="2011-01-04 15:03:34 +1100" MODIFIED_BY="[Empty name]" NAME="Maier 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-01-04 14:51:36 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain - results of a double-blind placebo-controlled trial (MONTAS)Clinical Trial; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2011-01-04 14:51:36 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maier C, Hildebrandt J, Klinger R, Henrich Eberl C, Lindena G, Group Montas Study</AU>
<TI>Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain - results of a double-blind placebo-controlled trial (MONTAS)</TI>
<SO>Pain</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>3</NO>
<PG>223-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-1984" MODIFIED="2011-09-17 23:55:47 +1000" MODIFIED_BY="[Empty name]" NAME="Mitchell 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-09-17 23:55:47 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Feb 18Research Support, Non-U.S. Gov'tAustralia&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:55:47 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell H, Cunningham TJ, Mathews JD, Muirden KD</AU>
<TI>Further look at dextropropoxyphene with or without paracetamol in the treatment of arthritis</TI>
<SO>Medical Journal of Australia</SO>
<YR>1984</YR>
<VL>140</VL>
<NO>4</NO>
<PG>224-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1978" MODIFIED="2011-09-17 23:56:21 +1000" MODIFIED_BY="[Empty name]" NAME="Murphy 1978" YEAR="1978">
<REFERENCE MODIFIED="2011-09-17 23:56:21 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Analgesic efficacy and acceptability of fenoprofen combined with paracetamol and compared with dihydrocodeine tartrate in general practiceClinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:56:21 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy JE, Donald JF, Layes Molla A</AU>
<TI>Analgesic efficacy and acceptability of fenoprofen combined with paracetamol and compared with dihydrocodeine tartrate in general practice</TI>
<SO>The Journal of International Medical Research</SO>
<YR>1978</YR>
<VL>6</VL>
<NO>5</NO>
<PG>375-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavelka-2004" MODIFIED="2011-01-04 15:03:42 +1100" MODIFIED_BY="[Empty name]" NAME="Pavelka 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-01-04 14:51:36 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DecBenefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: An open-label study to assess pain controlEnglishEnglish&lt;/p&gt;" NOTES_MODIFIED="2011-01-04 14:51:36 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavelka K, Le Loet X, Bjorneboe O, Herrero-Beaumont G, Richarz U</AU>
<TI>Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: An open-label study to assess pain control</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>12</NO>
<PG>1967-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raffaeli-2010" MODIFIED="2011-01-04 15:03:45 +1100" MODIFIED_BY="[Empty name]" NAME="Raffaeli 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-01-04 14:51:36 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;January-FebruaryOxycodone/acetaminophen at low dosage: An alternative pain treatment for patients with rheumatoid arthritisEnglishEnglish&lt;/p&gt;" NOTES_MODIFIED="2011-01-04 14:51:36 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raffaeli W, Pari C, Corvetta A, Sarti D, Di Sabatino V, Biasi G, et al</AU>
<TI>Oxycodone/acetaminophen at low dosage: An alternative pain treatment for patients with rheumatoid arthritis</TI>
<SO>Journal of Opioid Management</SO>
<YR>2010</YR>
<VL>6</VL>
<NO>1</NO>
<PG>40-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruoff-1999" MODIFIED="2011-09-17 23:56:58 +1000" MODIFIED_BY="[Empty name]" NAME="Ruoff 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-09-17 23:56:58 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Slowing the initial titration rate of tramadol improves tolerabilityClinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:56:58 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruoff GE</AU>
<TI>Slowing the initial titration rate of tramadol improves tolerability</TI>
<SO>Pharmacotherapy</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>1</NO>
<PG>88-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saleem-1998" MODIFIED="2011-09-17 23:57:23 +1000" MODIFIED_BY="[Empty name]" NAME="Saleem 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-09-17 23:57:23 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Intra-articular bupivacaine plus opioid for chronic joint pain&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:57:23 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saleem M, Kazi WA</AU>
<TI>Intra-articular bupivacaine plus opioid for chronic joint pain</TI>
<SO>Pakistan Journal of Medical Research</SO>
<YR>1998</YR>
<VL>37</VL>
<NO>3</NO>
<PG>104-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1999" MODIFIED="2011-01-04 15:04:00 +1100" MODIFIED_BY="[Empty name]" NAME="Stein 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-01-04 14:51:36 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Intraarticular morphine versus dexamethasone in chronic arthritisClinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.&lt;/p&gt;" NOTES_MODIFIED="2011-01-04 14:51:36 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein A, Yassouridis A, Szopko C, Helmke K, Stein C</AU>
<TI>Intraarticular morphine versus dexamethasone in chronic arthritis</TI>
<SO>Pain</SO>
<YR>1999</YR>
<VL>83</VL>
<NO>3</NO>
<PG>525-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vlak-1996" MODIFIED="2011-01-31 22:00:50 +1100" MODIFIED_BY="[Empty name]" NAME="Vlak 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-01-31 22:00:20 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[Tramadol (Tramal) in the treatment of rheumatic diseases-- comparative study]Mjesto tramadola (&amp;quot;Tramal&amp;quot;) u terapiji reumatskih bolesti--komparativno istrazivanje.&lt;br&gt;Clinical Trial; Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2011-01-31 22:00:20 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vlak T</AU>
<TI>[Tramadol (Tramal) in the treatment of rheumatic diseases-- comparative study]</TI>
<SO>Reumatizam</SO>
<YR>1996</YR>
<VL>43</VL>
<NO>2</NO>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziegler-2010" MODIFIED="2011-09-17 23:58:09 +1000" MODIFIED_BY="[Empty name]" NAME="Ziegler 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-09-17 23:58:09 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Analgesic effects of intra-articular morphine in patients with temporomandibular joint disorders: a prospective, double-blind, placebo-controlled clinical trialJournal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:58:09 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziegler CM, Wiechnik J, Mühling J</AU>
<TI>Analgesic effects of intra-articular morphine in patients with temporomandibular joint disorders: a prospective, double-blind, placebo-controlled clinical trial</TI>
<SO>Journal of Oral and Maxillofacial Surgery</SO>
<YR>2010</YR>
<VL>68</VL>
<NO>3</NO>
<PG>622-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zlnay-2001" MODIFIED="2011-01-31 22:19:15 +1100" MODIFIED_BY="[Empty name]" NAME="Zlnay 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-01-31 22:19:15 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Dihydrocodein (DHC continus) in the treatment of the rheumatoid arthritis. [Slovak]Dihydrokodein (DHC continus) v liecbe reumatoidnej artritidy.&lt;br&gt;English, Slovak&lt;/p&gt;" NOTES_MODIFIED="2011-01-31 22:19:15 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zlnay D, Struharova S, Rovensky J</AU>
<TI>Dihydrocodein (DHC continus) in the treatment of the rheumatoid arthritis. [Slovak]</TI>
<SO>Rheumatologia</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>3</NO>
<PG>103-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-09-17 23:59:06 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Pavelka-1984" MODIFIED="2011-01-31 22:01:18 +1100" MODIFIED_BY="[Empty name]" NAME="Pavelka 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-01-04 15:02:15 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Apr 6Clinical Trial&lt;br&gt;Comparative Study&lt;br&gt;English AbstractCzech&lt;br&gt;CzechoslovakiaCzech&lt;/p&gt;" NOTES_MODIFIED="2011-01-04 15:02:15 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavelka K, Tellerova K, Trnavsky K</AU>
<TI>[Drug therapy of pain in patients with rheumatoid arthritis]</TI>
<SO>Casopis Lekaru Ceskych</SO>
<YR>1984</YR>
<VL>123</VL>
<NO>14</NO>
<PG>407-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tadashi-1972" MODIFIED="2011-09-17 23:59:06 +1000" MODIFIED_BY="[Empty name]" NAME="Tadashi 1972" YEAR="1972">
<REFERENCE MODIFIED="2011-09-17 23:59:06 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;[ Analgesic Effect of d-Propoxyphene Napsylate (S-9700) on Pain in Rheumatoid Arthritis ]d-Propoxyphene Napsylate(S-9700) no Mansei Kansetsu Riumachi no Totsu ni Taisuru Chintsu Koka&lt;/p&gt;" NOTES_MODIFIED="2011-09-17 23:59:06 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tadashi Yamamoto</AU>
<TI>[Analgesic effect of d-propoxyphene napsylate (S-9700) on pain in rheumatoid arthritis]</TI>
<SO>Clinical Report: Kiso to Rinsho</SO>
<YR>1972</YR>
<VL>6</VL>
<NO>3</NO>
<PG>709-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-09-18 16:25:47 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-09-18 16:25:47 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACR-2002" MODIFIED="2011-09-18 00:01:44 +1000" MODIFIED_BY="[Empty name]" NAME="ACR 2002" TYPE="JOURNAL_ARTICLE">
<AU>ACR</AU>
<TI>Guidelines for the management of rheumatoid arthritis: 2002 update</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>2</NO>
<PG>328-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alarcon-1995" MODIFIED="2010-10-25 15:15:09 +1100" MODIFIED_BY="[Empty name]" NAME="Alarcon 1995" TYPE="JOURNAL_ARTICLE">
<AU>Alarcon GS</AU>
<TI>Epidemiology of rheumatoid arthritis</TI>
<SO>Rheumatic Diseases Clinics of North America</SO>
<YR>1995</YR>
<VL>21</VL>
<PG>589-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boada-2008" MODIFIED="2011-01-04 11:45:29 +1100" MODIFIED_BY="[Empty name]" NAME="Boada 2008" TYPE="JOURNAL_ARTICLE">
<AU>Boada J N, Boada C, Garcia-Saiz M, Garcia M, Fernandez E, Gomez E</AU>
<TI>Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance</TI>
<SO>PloS one</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>10</NO>
<PG>e3580</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cates-2004" MODIFIED="2010-09-28 17:32:09 +1000" MODIFIED_BY="[Empty name]" NAME="Cates 2004" TYPE="OTHER">
<AU>Cates C</AU>
<TI>Dr Chris Cates' EBM Web Site. Visual Rx Version 3</TI>
<SO>Available from: http://www.nntonline.net/visualrx/</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chu-2008" MODIFIED="2011-01-04 13:05:46 +1100" MODIFIED_BY="[Empty name]" NAME="Chu 2008" TYPE="JOURNAL_ARTICLE">
<AU>Chu L F, Angst M S, Clark D</AU>
<TI>Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>6</NO>
<PG>479-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeAngelis-2004" MODIFIED="2010-10-25 15:15:35 +1100" MODIFIED_BY="[Empty name]" NAME="DeAngelis 2004" TYPE="JOURNAL_ARTICLE">
<AU>DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al</AU>
<TI>Clinical trial registration: a statement from the International Committee of Medical Journal Editors</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>292</VL>
<NO>11</NO>
<PG>1363-4</PG>
<IDENTIFIERS MODIFIED="2010-09-07 13:55:16 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15355936"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2009" MODIFIED="2011-09-18 00:00:17 +1000" MODIFIED_BY="[Empty name]" NAME="Deeks 2009" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Higgins JPT and Altman DG on behalf of the Cochrane Statistical Methods Group (Editors)</AU>
<TI>Chapter 9:  Analysing data and undertaking meta-analyses </TI>
<SO>Higgins JFT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</SO>
<YR>2009</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS MODIFIED="2010-10-25 17:51:03 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-10-25 17:51:03 +1100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Available from www.cochrane-handbook.org"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dworkin-2008" MODIFIED="2011-09-18 16:21:09 +1000" MODIFIED_BY="[Empty name]" NAME="Dworkin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al</AU>
<TI>Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations</TI>
<SO>The Journal of Pain</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>2</NO>
<PG>105-21</PG>
<IDENTIFIERS MODIFIED="2010-10-28 08:25:44 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18055266"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2011-09-18 00:01:03 +1000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fields-1980" MODIFIED="2010-09-06 16:26:20 +1000" MODIFIED_BY="[Empty name]" NAME="Fields 1980" TYPE="JOURNAL_ARTICLE">
<AU>Fields HL, Emson PC, Leigh BK, Gilbert RF, Iversen LL</AU>
<TI>Multiple opiate receptor sites on primary afferent fibres</TI>
<SO>Nature</SO>
<YR>1980</YR>
<VL>284</VL>
<NO>5754</NO>
<PG>351-3</PG>
<IDENTIFIERS MODIFIED="2010-09-06 16:26:17 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="6244504"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fitzcharles-2009" MODIFIED="2011-09-18 16:21:32 +1000" MODIFIED_BY="[Empty name]" NAME="Fitzcharles 2009" TYPE="JOURNAL_ARTICLE">
<AU>Fitzcharles MA, DaCosta D, Ware MA, Shir Y</AU>
<TI>Patient barriers to pain management may contribute to poor pain control in rheumatoid arthritis</TI>
<SO>The Journal of Pain</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>3</NO>
<PG>300-5</PG>
<IDENTIFIERS MODIFIED="2010-09-06 16:26:31 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19070549"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fries-1980" MODIFIED="2010-10-25 15:16:29 +1100" MODIFIED_BY="[Empty name]" NAME="Fries 1980" TYPE="JOURNAL_ARTICLE">
<AU>Fries JF, Spitz P, Kraines RG, Holman HR</AU>
<TI>Measurement of patient outcome in arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1980</YR>
<VL>23</VL>
<NO>2</NO>
<PG>137-45</PG>
<IDENTIFIERS MODIFIED="2010-04-11 22:47:30 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="7362664"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Furlan-2006" MODIFIED="2011-09-18 16:23:42 +1000" MODIFIED_BY="[Empty name]" NAME="Furlan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E</AU>
<TI>Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects</TI>
<SO>CMAJ: Canadian Medical Association Journal</SO>
<YR>2006</YR>
<VL>174</VL>
<NO>11</NO>
<PG>1589-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldman-2006" MODIFIED="2011-09-06 17:12:11 +1000" MODIFIED_BY="[Empty name]" NAME="Goldman 2006" TYPE="BOOK">
<AU>Goldman A, Hain R, Liben S</AU>
<SO>Oxford Textbook of Palliative Care for Children</SO>
<YR>2006</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grijalva-2008" MODIFIED="2010-10-25 15:16:51 +1100" MODIFIED_BY="[Empty name]" NAME="Grijalva 2008" TYPE="JOURNAL_ARTICLE">
<AU>Grijalva CG, Chung CP, Stein CM, Mitchel E F Jr, Griffin MR</AU>
<TI>Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population</TI>
<SO>Rheumatology</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>7</NO>
<PG>1061-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heiberg-2002" MODIFIED="2010-10-25 15:17:20 +1100" MODIFIED_BY="[Empty name]" NAME="Heiberg 2002" TYPE="JOURNAL_ARTICLE">
<AU>Heiberg T, Kvien TK</AU>
<TI>Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>4</NO>
<PG>391-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009a" MODIFIED="2011-09-18 00:02:27 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2009a" TYPE="OTHER">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2010-10-26 13:45:38 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009b" MODIFIED="2011-09-18 00:03:01 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2009b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics</TI>
<SO>In: Higgins JPT, Green S, editors, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2010-10-26 13:46:46 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009c" MODIFIED="2011-09-18 16:24:18 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2009c" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ (editors)</AU>
<TI>Chapter 7: Selecting studies and collecting data</TI>
<SO>In: Higgins JPT, Green S, editors, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2010-10-26 13:47:53 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Hudcova-2006" MODIFIED="2010-10-25 15:19:04 +1100" MODIFIED_BY="[Empty name]" NAME="Hudcova 2006" TYPE="COCHRANE_REVIEW">
<AU>Hudcova J, McNicol ED, Quah CS, Lau J, Carr DB</AU>
<TI>Patient controlled opioid analgesia versus conventional opioid analgesia for postoperative pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-10-25 15:18:57 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-10-25 15:18:57 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003348.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kvien-2004" MODIFIED="2011-09-18 00:03:36 +1000" MODIFIED_BY="[Empty name]" NAME="Kvien 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kvien TK</AU>
<TI>Epidemiology and burden of illness of rheumatoid arthritis</TI>
<SO>Pharmacoeconomics</SO>
<YR>2004</YR>
<VL>22 Suppl 1</VL>
<NO>2</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lang-2010" MODIFIED="2010-09-06 16:26:45 +1000" MODIFIED_BY="[Empty name]" NAME="Lang 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lang LJ, Pierer M, Stein C, Baerwald C</AU>
<TI>Opioids in rheumatic diseases</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2010</YR>
<VL>1193</VL>
<NO>1</NO>
<PG>111-6</PG>
<IDENTIFIERS MODIFIED="2010-09-06 16:26:44 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20398015"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Luqmani-2009" MODIFIED="2010-09-28 17:34:49 +1000" MODIFIED_BY="[Empty name]" NAME="Luqmani 2009" TYPE="JOURNAL_ARTICLE">
<AU>Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A, et al</AU>
<TI>British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years)</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2009</YR>
<VL>48</VL>
<NO>4</NO>
<PG>436-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDougall-2006" MODIFIED="2010-10-25 15:19:59 +1100" MODIFIED_BY="[Empty name]" NAME="McDougall 2006" TYPE="JOURNAL_ARTICLE">
<AU>McDougall JJ</AU>
<TI>Arthritis and pain. Neurogenic origin of joint pain</TI>
<SO>Arthritis Research &amp; Therapy</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>6</NO>
<PG>220</PG>
<IDENTIFIERS MODIFIED="2010-09-06 16:26:55 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17118212"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Minnock-2003" MODIFIED="2010-10-25 15:20:14 +1100" MODIFIED_BY="[Empty name]" NAME="Minnock 2003" TYPE="JOURNAL_ARTICLE">
<AU>Minnock P, FitzGerald O, Bresnihan B</AU>
<TI>Women with established rheumatoid arthritis perceive pain as the predominant impairment of health status</TI>
<SO>Rheumatology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>8</NO>
<PG>995-1000</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2005" MODIFIED="2011-09-18 16:25:47 +1000" MODIFIED_BY="[Empty name]" NAME="Moore 2005" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, McQuay HJ</AU>
<TI>Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids</TI>
<SO>Arthritis Research &amp; Therapy</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>5</NO>
<PG>R1046-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2010a" MODIFIED="2011-01-04 14:34:14 +1100" MODIFIED_BY="[Empty name]" NAME="Moore 2010a" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al</AU>
<TI>"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews</TI>
<SO>Pain</SO>
<YR>2010</YR>
<VL>150</VL>
<NO>3</NO>
<PG>386-9</PG>
<IDENTIFIERS MODIFIED="2010-10-28 08:21:43 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20627575"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2010b" MODIFIED="2011-09-18 00:04:22 +1000" MODIFIED_BY="[Empty name]" NAME="Moore 2010b" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Derry S, McQuay HJ, Straube S, Aldington D, Wiffen P, et al</AU>
<TI>Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences</TI>
<SO>Pain</SO>
<YR>2010</YR>
<VL>149</VL>
<NO>2</NO>
<PG>173-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Noble-2010" MODIFIED="2010-10-25 15:21:13 +1100" MODIFIED_BY="[Empty name]" NAME="Noble 2010" TYPE="COCHRANE_REVIEW">
<AU>Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al</AU>
<TI>Long-term opioid management for chronic noncancer pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-10-25 15:21:13 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006605.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nuesch-2009" MODIFIED="2011-09-18 00:05:18 +1000" MODIFIED_BY="[Empty name]" NAME="Nuesch 2009" TYPE="COCHRANE_REVIEW">
<AU>Nuesch E, Rutjes AW, Husni E, Welch V, Juni P</AU>
<TI>Oral or transdermal opioids for osteoarthritis of the knee or hip</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-09-05 11:42:52 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-09-05 11:42:52 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003115.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pincus-1983" MODIFIED="2010-10-25 15:21:39 +1100" MODIFIED_BY="[Empty name]" NAME="Pincus 1983" TYPE="JOURNAL_ARTICLE">
<AU>Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP</AU>
<TI>Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1983</YR>
<VL>26</VL>
<NO>11</NO>
<PG>1346-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raffa-1992" MODIFIED="2010-10-25 15:22:04 +1100" MODIFIED_BY="[Empty name]" NAME="Raffa 1992" TYPE="JOURNAL_ARTICLE">
<AU>Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL</AU>
<TI>Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1992</YR>
<VL>260</VL>
<NO>1</NO>
<PG>275-85</PG>
<IDENTIFIERS MODIFIED="2010-09-06 16:21:58 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="1309873"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rhodin-2010" MODIFIED="2011-01-04 13:05:51 +1100" MODIFIED_BY="[Empty name]" NAME="Rhodin 2010" TYPE="JOURNAL_ARTICLE">
<AU>Rhodin A, Stridsberg M, Gordh T</AU>
<TI>Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>5</NO>
<PG>374-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008a" MODIFIED="2010-10-25 10:33:10 +1100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008a" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and &#8216;Summary of findings' tables</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008) The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<CY>www.cochrane-handbook.org</CY>
<IDENTIFIERS MODIFIED="2010-09-28 17:15:23 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008b" MODIFIED="2011-09-18 00:06:13 +1000" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008b" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>In: Higgins JPT, Green S, editors, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<CY>www.cochrane-handbook.org</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2008" MODIFIED="2011-09-18 00:06:40 +1000" MODIFIED_BY="[Empty name]" NAME="Sterne 2008" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Moher D (editors)</AU>
<TI>Chapter 10: Addressing reporting biases</TI>
<SO>In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Intervention. Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiffen-2007" MODIFIED="2010-10-25 10:36:16 +1100" MODIFIED_BY="[Empty name]" NAME="Wiffen 2007" TYPE="COCHRANE_REVIEW">
<AU>Wiffen PJ, McQuay HJ</AU>
<TI>Oral morphine for cancer pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-10-25 10:35:50 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003868.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-09-18 16:02:14 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-09-18 16:02:14 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-02-02 18:15:53 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bedi-1969">
<CHAR_METHODS MODIFIED="2011-01-10 15:03:40 +1100" MODIFIED_BY="[Empty name]">
<P>Cross-over trial. Method of randomization of treatment order not described</P>
<P>Blinding: subjects and investigator blinded; matching tablets used</P>
<P>WIthdrawals: 6 participants</P>
<P>Sample size calculation: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 18:15:53 +1100" MODIFIED_BY="[Empty name]">
<P>51 participants with "definite or classical" rheumatoid arthritis and "moderate to severe arthritic pain" (not further defined)</P>
<P>Disease duration: not reported</P>
<P>Age and gender not reported</P>
<P>DMARD therapy: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-01 23:03:45 +1100" MODIFIED_BY="[Empty name]">
<P>Two interventions of duration one week each in cross-over design; no washout period</P>
<P>Intervention 1: Aspirin tablet 500mg tds for 2 days, then 1g tds for 5 days</P>
<P>Intervention 2: Aspirin plus dextropropoxyphene tablet: aspirin 500mg plus dextropropoxyphene 50mg tds for 2 days, then aspirin 1g plus dextropropoxyphene 100mg tds for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-01 23:07:09 +1100" MODIFIED_BY="[Empty name]">
<P>Assessed at end of week 1 and week 2:</P>
<P>Patient assessment of treatment efficacy ("better", "no change", "worse")</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-01-10 15:03:32 +1100" MODIFIED_BY="[Empty name]">
<P>Random allocation of treatment order is implied but not made explicit. No method for randomization is described. Quote: "The hospital pharmacist alone knew what drug each patient had received."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-18 15:56:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boureau-1991">
<CHAR_METHODS MODIFIED="2010-12-05 14:01:11 +1100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
<P>Duration: 7 days</P>
<P>Randomization method: not described</P>
<P>Blinding: both participants and investigators (presumed to be the outcome assessors) were blinded</P>
<P>WIthdrawals: one participant</P>
<P>Sample size calculation: 40 patients "estimated" to have been sufficient; no calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-17 23:35:06 +1000" MODIFIED_BY="[Empty name]">
<P>40 participants, 36 females and 4 males</P>
<P>Mean age 56.9 years</P>
<P>Diagnosis: rheumatoid arthritis (ARA criteria) on stable doses of background therapy for at least one month (mean disease duration 96.3 months)</P>
<P>DMARD therapy: stable therapy permitted to continue (proportion not reported)</P>
<P>Inclusion criteria: persistent residual pain; pain at least 'moderate' on 5-point verbal rating scale in 24 hours prior to randomization</P>
<P>Exclusion criteria: contraindication to codeine or paracetamol; history of opioid abuse; use of an anti-inflammatory drug other than usual therapy in 48 hours prior to randomization</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-17 23:35:28 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: codeine 30mg plus paracetamol 500mg three times daily (7am, 1pm, 8pm)</P>
<P>Group 2: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-01 23:39:25 +1100" MODIFIED_BY="[Empty name]">
<P>Primary efficacy measures:</P>
<P>1. Patient assessment of overall efficacy (5-point verbal rating scale) at one week</P>
<P>2. Physician assessment of overall efficacy (5-point verbal rating scale) at one week</P>
<P>Secondary efficacy measures:</P>
<P>1. Daily pain score (100mm visual analogue scale)</P>
<P>2. Daily disability score (4-point scale)</P>
<P>3. Number of pain-related nocturnal awakenings, recorded daily</P>
<P>4. Pain relief (unchanged, worse, &lt;50% relief, &gt;50% relief) at one week</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-18 15:56:49 +1000" MODIFIED_BY="[Empty name]">
<P>One participant was mistakenly enrolled despite reporting only "slight" pain in the 24 hours before randomization - this subject was excluded from the efficacy analysis but was included in the safety analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-17 23:37:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brunnmuller-2004">
<CHAR_METHODS MODIFIED="2011-02-02 18:16:07 +1100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
<P>Duration: 6 weeks (2 weeks dose titration phase, 4 weeks treatment phase)</P>
<P>Randomization method: not described</P>
<P>Blinding: participants and investigators were blinded</P>
<P>WIthdrawals: one subject, excluded from all analyses</P>
<P>Sample size calculation: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 18:16:15 +1100" MODIFIED_BY="[Empty name]">
<P>19 participants, 13 females and 6 males</P>
<P>Mean age 58 years (intervention group), 56 years (placebo group); age range 52-71 years (intervention group), 38-79 years (placebo group)</P>
<P>Diagnosis: Rheumatoid arthritis (ACR criteria)</P>
<P>Disease duration: not reported</P>
<P>DMARD therapy: stable therapy permitted to continue (proportion not reported)</P>
<P>Inclusion criteria: Pain on 10cm VAS &gt;5cm; pain for at least one month prior to entry; pain for at least 6 hours per day</P>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-17 23:37:26 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: Tilidine/naloxone 50mg/4mg or 100mg/8mg or 150mg/12mg</P>
<P>Group 2: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-05 13:31:51 +1100" MODIFIED_BY="[Empty name]">
<P>All outcomes assessed at 6 weeks:</P>
<P>1. Pain (10cm visual analogue scale)</P>
<P>2. Number of swollen joints</P>
<P>3. Number of tender joints</P>
<P>4. Pain-related sleep disturbance</P>
<P>5. Quality of life (McGill pain questionnaire)</P>
<P>6. Global efficacy (better, no change, worse)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-06 17:32:15 +1000" MODIFIED_BY="[Empty name]">
<P>Pain VAS scores at 6 weeks were reported as median and range only. An estimate of mean and SD was not made from these data, in accordance with the recommendations in the Cochrane Handbook (Ch 7.7.3.6) (<LINK REF="REF-Higgins-2009c" TYPE="REFERENCE">Higgins 2009c</LINK>), and these data were not used for meta-analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-17 23:38:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glowinski-1999">
<CHAR_METHODS MODIFIED="2010-12-05 14:03:38 +1100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
<P>Duration: 7 days</P>
<P>Randomization method: not described</P>
<P>Blinding: described as "double-blind"; no further details given</P>
<P>WIthdrawals: 2 participants</P>
<P>Sample size calculation: 60 participants "estimated...on the basis of previous available studies". No calculation reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 18:17:07 +1100" MODIFIED_BY="[Empty name]">
<P>60 participants, 50 females, 10 males</P>
<P>Mean age (SD): 54.8 (16.1) years (paracetamol-codeine group); 59.4 (9.9) years (diclofenac group)</P>
<P>Diagnosis: rheumatoid arthritis (ACR criteria)</P>
<P>Mean disease duration (SD): 10.6 (9.6) years (paracetamol-codeine group); 7 (4.8) years (diclofenac group)</P>
<P>DMARD therapy: stable therapy permitted to continue (53 of 60 participants)</P>
<P>Inclusion criteria: stable background antirheumatic therapy for at least 2 months; pain in 24 hours before randomization at least 'moderate' on a 5-point verbal rating scale</P>
<P>Exclusion criteria: relative contraindication to paracetamol or codeine; previous opioid abuse</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-17 23:38:17 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: Paracetamol 500mg + codeine 30mg tablet three times daily, plus diclofenac 50mg at 7pm, plus placebo (matching diclofenac) at 8am</P>
<P>Group 2: Diclofenac 50mg tablet at 8am and 7pm, plus placebo (matching paracetamol+codeine) three times daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-05 14:19:08 +1100" MODIFIED_BY="[Empty name]">
<P>1. Patient global efficacy rating (5-point verbal rating scale) at 7 days</P>
<P>2. Physician global efficacy rating (5-point verbal rating scale) at 7 days</P>
<P>3. Pain (100mm VAS) at 7 days</P>
<P>4. Daily pain (100mm VAS), measured daily</P>
<P>5. Disability score (4-point verbal rating scale), measured daily</P>
<P>6. Number of nocturnal awakenings, measured daily</P>
<P>7. Duration of morning stiffness, measured daily</P>
<P>8. Intention to resume treatment, at 7 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-05 14:20:10 +1100" MODIFIED_BY="[Empty name]">
<P>No details given for power calculation. Results reported as for an equivalence study, although not apparently powered as such.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-02 18:17:13 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hardin-1979">
<CHAR_METHODS MODIFIED="2010-12-05 14:28:10 +1100" MODIFIED_BY="[Empty name]">
<P>Sequential cross-over study of single doses of five different analgesic drugs</P>
<P>Sequence of administration randomized by hospital pharmacist</P>
<P>Blinding: participants, study personnel and investigators were blinded. The code for the sequence of drug administration was kept by the hospital pharmacist</P>
<P>Withdrawals: zero</P>
<P>Sample size calculation: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 18:17:13 +1100" MODIFIED_BY="[Empty name]">
<P>30 participants</P>
<P>Age and gender not reported</P>
<P>Diagnosis: rheumatoid arthritis (ARA criteria)</P>
<P>Disease duration: not reported</P>
<P>DMARD therapy: stable therapy permitted to continue (proportion not reported)</P>
<P>Inclusion criteria: persistent pain in at least 4 joints; no recent improvement in disease control</P>
<P>Exclusion criteria: regular glucocorticoid use; regular narcotic analgesic use; severe mechanical pain due to degenerative disease; DMARDs commenced within 6 months of entry to study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-05 14:36:29 +1100" MODIFIED_BY="[Empty name]">
<P>Each participant received each of 6 capsules (5 active agents, below, plus placebo) sequentially as required for pain, no sooner than 6 hours after the most recent study drug:</P>
<P>1. Aspirin 650mg</P>
<P>2. Paracetamol 650mg</P>
<P>3. Codeine sulphate 65mg</P>
<P>4. Propoxyphene hydrochloride 65mg</P>
<P>5. Pentazocine hydrochloride 50mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-05 14:40:27 +1100" MODIFIED_BY="[Empty name]">
<P>1. Analgesic effectiveness by rank, measured at 6 hours after 6th capsule administered</P>
<P>2. Pain relief (as proportion of complete abolition of pain)</P>
<P>3. Time to maximum analgesia</P>
<P>4. Time to recurrence of pain</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-05 15:20:23 +1100" MODIFIED_BY="[Empty name]">
<P>Data from 30 participants who completed the study were presented. Unclear whether there were participants who did not complete the study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-17 23:39:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hill-1970">
<CHAR_METHODS MODIFIED="2010-12-05 15:21:50 +1100" MODIFIED_BY="[Empty name]">
<P>Sequential cross-over study of single doses of three active interventions plus placebo</P>
<P>Randomization method: sequence of administration randomized by latin square design over sets of four patients</P>
<P>Blinding: participants and investigators blinded to treatment sequence</P>
<P>Withdrawals: zero</P>
<P>Sample size calculation: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-17 23:39:07 +1000" MODIFIED_BY="[Empty name]">
<P>40 participants</P>
<P>Age range 20-70 years</P>
<P>Gender not reported</P>
<P>Diagnosis: rheumatoid arthritis (diagnostic criteria not reported)</P>
<P>Disease duration: not reported</P>
<P>DMARD therapy: not reported</P>
<P>Inclusion criteria: requirement for regular analgesic medications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-17 23:39:36 +1000" MODIFIED_BY="[Empty name]">
<P>Each participant received each of four treatments sequentially on four consecutive mornings:</P>
<P>1. Codeine phosphate 8mg + acetylsalicylic acid 250mg + phenacetin 250mg, two tablets, plus two placebo tablets</P>
<P>2. Isopropylantipyrine 150mg + phenacetin 250mg + caffeine 50mg, 2 tablets, plus two placebo tablets</P>
<P>3. Isopropylantipyrine 150mg + phenacetin 250mg + caffeine 50mg, 4 tablets</P>
<P>4. Placebo, 4 tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-05 15:34:20 +1100" MODIFIED_BY="[Empty name]">
<P>Pain relief (5-point verbal rating scale) at 30, 60, 90, 120 minutes, 4.5 hours and 6 hours after administration of study drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-05 15:36:00 +1100" MODIFIED_BY="[Empty name]">
<P>All participants were administered placebo before entry into the study, those who reported "definite" pain relief were excluded prior to randomization. The number of participants who were excluded was not reported.</P>
<P>Outcome measures not clearly reported. Maximum pain relief score (of six scores after each dose of study drug) appears to have been used for statistical analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-18 15:59:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huskisson-1974">
<CHAR_METHODS MODIFIED="2011-09-17 23:40:15 +1000" MODIFIED_BY="[Empty name]">
<P>Three consecutive trials of similar design</P>
<P>Trial 1: Comparison of single doses of 4 interventions (3 analgesic tablets and placebo) in a sequential pairwise cross-over design</P>
<P>Trial 2: Comparison of single doses of 4 interventions (3 soluble analgesics and placebo) in a sequential pairwise cross-over design</P>
<P>Trial 3: Comparison of single doses of 3 interventions (2 analgesic tablets and placebo) in a sequential pairwise cross-over design</P>
<P>Randomization method: order of treatment allocation in each pairwise comparison was randomized, but the method of randomization is not described</P>
<P>Blinding: participants and investigators blinded to treatment sequence</P>
<P>Withdrawals: 78 participants were randomized across the three trials but data from 67 participants were analyzed</P>
<P>Sample size calculation: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 18:17:30 +1100" MODIFIED_BY="[Empty name]">
<P>30 participants in trial 1, 24 participants in trial 2, 24 participants in trial 3</P>
<P>Age and gender not reported</P>
<P>Diagnosis: rheumatoid arthritis (ARA criteria)</P>
<P>Disease duration: not reported</P>
<P>DMARD therapy: not reported</P>
<P>Inclusion criteria: pain of sufficient severity to require "on-demand" analgesic medications at least once a day</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-06 15:31:13 +1100" MODIFIED_BY="[Empty name]">
<P>For each participant, single doses of different interventions were compared in pairs, where each intervention was given once, on consecutive days. Each participant within a trial received all possible treatment pairs (6 comparisons in trials 1 and 2, 3 comparisons in trial 3), with one day of 'usual therapy' between each paired comparison. The interventions were: </P>
<P>Trial 1: </P>
<P>1. paracetamol 325mg + dextropropoxyphene 32.5mg, 2 tablets, plus 2 placebo tablets </P>
<P>2. paracetamol 500mg, 2 tablets, plus 2 placebo tablets </P>
<P>3. pentazocine 25mg, 2 tablets, plus 2 placebo tablets</P>
<P>4. placebo, 4 tablets</P>
<P>Trial 2: </P>
<P>1. aspirin 500mg + codeine 8mg, 2 soluble tablets, plus 2 soluble placebo tablets</P>
<P>2. paracetamol 325mg + dextropropoxyphene 32.5mg, 2 soluble tablets, plus 2 soluble placebo tablets </P>
<P>3. aspirin 300mg, 2 soluble tablets, plus 2 soluble placebo tablets</P>
<P>4. placebo, 4 soluble tablets</P>
<P>Trial 3: </P>
<P>1. 'Ciba 44,328' (an experimental compound related to propoxyphene) 50mg, 2 tablets, plus 2 placebo tablets</P>
<P>2. paracetamol, 2 tablets, plus 2 placebo tablets</P>
<P>3. placebo, 4 tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-06 15:33:00 +1100" MODIFIED_BY="[Empty name]">
<P>1. pain relief (4-point verbal rating scale), measured hourly for six hours after administration of study drug</P>
<P>2. patient preference, after each pairwise comparison</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-18 15:59:16 +1000" MODIFIED_BY="[Empty name]">
<P>It is not clear whether any subjects participated in more than one trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-02 18:17:38 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2006">
<CHAR_METHODS MODIFIED="2010-12-06 16:05:19 +1100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
<P>Duration: 7 days</P>
<P>Randomization method: participants were randomized to active treatment or placebo in 3:1 ratio. Randomization method not described</P>
<P>Blinding: participants, investigators and clinical personnel were blinded to treatment assignment</P>
<P>Withdrawals: 10 participants were excluded from the 'intention to treat' efficacy analysis after randomization; 5 participants who had been randomized were not included in the tolerability analysis</P>
<P>Sample size calculation: 126 in the active treatment group and 42 in the placebo group were estimated to be required to detect a difference in mean daily pain relief of 0.4, at alpha=0.05, power=0.8</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 18:17:38 +1100" MODIFIED_BY="[Empty name]">
<P>277 participants randomized, 267 (227 females and 40 males) included in the analysis</P>
<P>Active treatment group: 171 females and 30 males, mean age 51.55 (range 24-76)</P>
<P>Placebo group: 56 females and 10 males, mean age 52.02 (range 26-74)</P>
<P>Diagnosis: rheumatoid arthritis (ACR criteria), diagnosed at least 6 months prior to enrolment in trial</P>
<P>Disease duration: not reported (diagnosis at least 6 months prior required for study entry)</P>
<P>DMARD therapy: stable therapy permitted to continue (94.0% in active treatment group, 92.4% in placebo group)</P>
<P>Inclusion criteria: Pain due to rheumatoid arthritis of severity at least 40mm on 100mm VAS for at least 2 days prior to randomization; stable background DMARD and NSAID therapy for at least 30 days</P>
<P>Exclusion criteria: concomitant use of SSRI antidepressants, short-acting analgesics, topical analgesics or anaesthetics within 5 half-lives prior to study entry; intra-articular glucocorticoids within 2 months prior to study entry; commencement of new DMARD therapy within 3 months or oral glucocorticoids within 4 weeks prior to study entry; other active articular disease; previous failure of, or intolerance to, tramadol; major psychiatric morbidity; history of substance abuse</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-06 16:45:46 +1100" MODIFIED_BY="[Empty name]">
<P>Group 1: tramadol 37.5mg + paracetamol 325mg, one tablet three times daily</P>
<P>Group 2: placebo, one tablet three times daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-06 16:50:02 +1100" MODIFIED_BY="[Empty name]">
<P>Primary:</P>
<P>1. Mean pain relief score (6-point scale), measured daily</P>
<P>Secondary:</P>
<P>1. Mean pain score (100mm VAS), measured daily</P>
<P>2. Pain (100mm VAS) at 7 days</P>
<P>3. Pain relief (6-point scale) at 7 days</P>
<P>4. Patient global assessment of efficacy (5-point Likert scale), measured at 7 days</P>
<P>5. Investigator global assessment of efficacy (5-point Likert scale), measured at 7 days</P>
<P>6. Function (Health Assessment Questionnaire), measured at 7 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-30 17:17:53 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-18 16:00:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moran-1991">
<CHAR_METHODS MODIFIED="2010-12-06 22:26:51 +1100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled cross-over trial</P>
<P>Duration: 10 weeks (5 weeks per phase)</P>
<P>Randomization method: order of intervention randomly allocated; the method of randomization was not described</P>
<P>Blinding: placebo was used but no further details of blinding procedure were provided</P>
<P>Withdrawals: 16 participants failed to complete the study, 11 of whom withdrew during the first phase</P>
<P>Sample size calculation: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-16 15:55:00 +1100" MODIFIED_BY="[Empty name]">
<P>20 participants (19 males and one female)</P>
<P>Age not reported</P>
<P>Diagnosis: rheumatoid arthritis (diagnostic criteria not reported)</P>
<P>Disease duration: not reported</P>
<P>DMARD therapy: not reported</P>
<P>Inclusion criteria: pain poorly controlled by non-narcotic analgesics</P>
<P>Exclusion criteria: pregnancy or lactation; history of drug abuse; severe hepatic, renal, cardiac or respiratory comorbidity; prior sensitivity to trial medications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-06 22:28:20 +1100" MODIFIED_BY="[Empty name]">
<P>Two intervention phases of duration 5 weeks each in cross-over design; no washout period:</P>
<P>Intervention 1: Controlled-release morphine sulphate 10mg 12-hourly, titrated by the investigator in weeks 2 and 3 to achieve adequate analgesia (maximum dose 60mg 12-hourly), and gradually reduced in dose in the fifth week until cessation at the completion of 5 weeks</P>
<P>Intervention 2: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-18 16:00:28 +1000" MODIFIED_BY="[Empty name]">
<P>All outcomes were assessed at the completion of weeks 2, 4 and 5 in each intervention phase:</P>
<P>1. Pain (100mm VAS)</P>
<P>2. Pain verbal rating scale (4-point)</P>
<P>3. Function (Health Assessment Questionnaire)</P>
<P>4. Joint inflammation (Ritchie index)</P>
<P>5. Grip strength (sum of both hands, in mm Hg)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-12-06 22:48:25 +1100" MODIFIED_BY="[Empty name]">
<P>Due to the unexpectedly high number of withdrawals, the study was analysed as a parallel-group controlled trial at the completion of phase one, rather than as a cross-over trial. Data were analysed at the completion of weeks 2 and 4 of phase one, and only completers were included in the efficacy analysis.</P>
<P>The protocol allowed for titration of the morphine sulphate dose to a maximum of 120mg per day. The doses received by participants were not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-18 16:01:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nuki-1973">
<CHAR_METHODS MODIFIED="2010-12-06 23:04:09 +1100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled cross-over trial</P>
<P>Duration: 2 weeks (one week per phase)</P>
<P>Randomization method: order of intervention randomly allocated; the method of randomization was not described</P>
<P>Blinding: placebo was used but no further details of blinding procedure were provided</P>
<P>Withdrawals: 5 participants</P>
<P>Sample size calculation: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 18:17:58 +1100" MODIFIED_BY="[Empty name]">
<P>40 participants (29 females and 11 males)</P>
<P>Mean age 51.95 years (range 26-73)</P>
<P>Diagnosis: rheumatoid arthritis (1958 ARA criteria)</P>
<P>Mean disease duration 8.1 years (SD 8.2 years)</P>
<P>DMARD therapy: not permitted</P>
<P>Inclusion criteria: inadequate pain relief despite stable doses of NSAIDs for at least one month</P>
<P>Exclusion criteria: current use of glucocorticoids, chrysotherapy or anti-malarial drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-06 23:15:20 +1100" MODIFIED_BY="[Empty name]">
<P>Two intervention phases of duration one week each in cross-over design; no washout period:</P>
<P>Intervention 1: pentazocine 25mg, one tablet four-hourly by day plus 2 tablets on retiring</P>
<P>Intervention 2: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-06 23:18:13 +1100" MODIFIED_BY="[Empty name]">
<P>All outcomes were assessed at the completion of each one-week intervention phase:</P>
<P>1. Pain (5-point verbal rating scale)</P>
<P>2. Stiffness (5-point verbal rating scale)</P>
<P>3. Joint tenderness (Ritchie index)</P>
<P>4. Grip strength</P>
<P>At the completion of the second intervention phase, participants also recorded a preference for one of the interventions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-18 16:01:17 +1000" MODIFIED_BY="[Empty name]">
<P>5 participants withdrew prior to completion of the study and were excluded from analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-18 16:02:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saarialho-1988">
<CHAR_METHODS MODIFIED="2010-12-06 23:35:43 +1100" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled cross-over trial</P>
<P>Duration: Four one-week intervention phases, commenced at two-week intervals</P>
<P>Randomization method: order of interventions was randomly allocated; the method of randomization was not described</P>
<P>Blinding: placebo was used but no further details of blinding procedure were provided</P>
<P>Withdrawals: one participant</P>
<P>Sample size calculation: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-02 18:18:03 +1100" MODIFIED_BY="[Empty name]">
<P>16 participants (14 females and 2 males)</P>
<P>Age range 21-67 years</P>
<P>Diagnosis: rheumatoid arthritis (ARA criteria)</P>
<P>Mean disease duration 6.2 years (SD 8.0 years)</P>
<P>DMARD therapy: stable therapy permitted to continue (proportion not reported)</P>
<P>Inclusion criteria: daily anti-inflammatory analgesic use</P>
<P>Exclusion criteria: gastrointestinal, hepatic, renal or psychiatric disease; previous intolerance to study medications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-06 23:45:17 +1100" MODIFIED_BY="[Empty name]">
<P>Four intervention phases of duration one week each in cross-over design; one week washout period between each intervention phase:</P>
<P>Intervention 1: paracetamol 500mg twice daily on days 1-3, indomethacin 25mg three times daily on days 4-5, indomethacin 50mg on the morning of day 6</P>
<P>Intervention 2: paracetamol 500mg twice daily on days 1-3, dextropropoxyphene 65mg three times daily on days 4-5, dextropropoxyphene 130mg on the morning of day 6</P>
<P>Intervention 3: paracetamol 500mg twice daily on days 1-3, dextropropoxyphene 65mg mane and 2pm, plus amitriptyline 25mg nocte on days 4-5, dextropropoxyphene 65mg plus amitriptyline 25mg on the morning of day 6</P>
<P>Intervention 4: paracetamol 500mg twice daily on days 1-3, placebo three times daily on days 4-5, placebo on the morning of day 6</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-06 23:48:11 +1100" MODIFIED_BY="[Empty name]">
<P>All outcomes were assessed at 2 hours and 4 hours after the administration of the study drug on day 6 of each intervention phase:</P>
<P>Primary: psychomotor tests</P>
<P>Secondary: </P>
<P>1. pain (100mm VAS)</P>
<P>2. other subjective assessments, including drowsiness, mood, anxiety, contentment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-18 16:02:14 +1000" MODIFIED_BY="[Empty name]">
<P>One participant withdrew from the study and was not included in the analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-02-02 18:18:21 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:52:45 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berliner-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:52:45 +1100" MODIFIED_BY="[Empty name]">
<P>No comparator group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:53:20 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boureau-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:53:20 +1100" MODIFIED_BY="[Empty name]">
<P>Same study as Boureau 1991, published in a different language</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:53:30 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brooke-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:53:30 +1100" MODIFIED_BY="[Empty name]">
<P>No pain outcome measure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:53:55 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brooks-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:53:55 +1100" MODIFIED_BY="[Empty name]">
<P>Mixed population of OA and RA; data not able to be separated for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:54:12 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buus-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:54:12 +1100" MODIFIED_BY="[Empty name]">
<P>Not published as a full-text article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:54:28 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buus-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:54:28 +1100" MODIFIED_BY="[Empty name]">
<P>Not published as a full-text article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:54:42 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fancourt-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:54:42 +1100" MODIFIED_BY="[Empty name]">
<P>Mixed population of OA and RA; data not able to be separated for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:54:46 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flavell_x002d_Matts-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:54:46 +1100" MODIFIED_BY="[Empty name]">
<P>Mixed population of OA and RA; data not able to be separated for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:55:35 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gum-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:55:35 +1100" MODIFIED_BY="[Empty name]">
<P>Comparison of steroid versus no steroid; all participants received the same background opioid therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:55:43 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herrero_x002d_Beaumont-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:55:43 +1100" MODIFIED_BY="[Empty name]">
<P>No comparator group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:55:52 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ingpen-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:55:52 +1100" MODIFIED_BY="[Empty name]">
<P>No pain outcome measure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:56:20 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maier-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:56:20 +1100" MODIFIED_BY="[Empty name]">
<P>No participants with rheumatoid arthritis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:56:27 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mitchell-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:56:27 +1100" MODIFIED_BY="[Empty name]">
<P>Mixed population of OA and RA; data not able to be separated for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:56:39 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murphy-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:56:39 +1100" MODIFIED_BY="[Empty name]">
<P>Mixed population; data not able to be separated for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:56:55 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavelka-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:56:55 +1100" MODIFIED_BY="[Empty name]">
<P>No comparator group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:57:08 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raffaeli-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:57:08 +1100" MODIFIED_BY="[Empty name]">
<P>No comparator group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-10 14:54:25 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruoff-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-10 14:54:25 +1100" MODIFIED_BY="[Empty name]">
<P>Trial of tramadol in chronic joint pain but participants with rheumatoid arthritis were specifically excluded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:59:24 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saleem-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:59:24 +1100" MODIFIED_BY="[Empty name]">
<P>Mixed population; data not able to be separated for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-04 14:59:32 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stein-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-04 14:59:32 +1100" MODIFIED_BY="[Empty name]">
<P>Mixed population of OA and RA; data not able to be separated for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-02 18:18:19 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vlak-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-02 18:18:19 +1100" MODIFIED_BY="[Empty name]">
<P>Mixed population; data not able to be separated for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-10 14:57:21 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ziegler-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-10 14:57:21 +1100" MODIFIED_BY="[Empty name]">
<P>Trial of intra-articular morphine in temporomandibular joint disorders; participants with inflammatory arthritis were excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-02 18:18:21 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zlnay-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-02 18:18:21 +1100" MODIFIED_BY="[Empty name]">
<P>No comparator group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-02-02 18:18:27 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2011-02-02 18:18:27 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavelka-1984">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2011-02-02 18:18:27 +1100" MODIFIED_BY="[Empty name]">
<P>Awaiting translation</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-02-02 18:18:24 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tadashi-1972">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2011-02-02 18:18:24 +1100" MODIFIED_BY="[Empty name]">
<P>Awaiting translation</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-09-18 16:00:48 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-09-17 23:41:00 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:36:11 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bedi-1969">
<DESCRIPTION>
<P>Not described. Not clear that randomization occurred at all.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-28 16:01:38 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boureau-1991">
<DESCRIPTION>
<P>Quote: "This...randomized...study versus placebo was carried out in two parallel groups..."</P>
<P>Comment: Method of sequence generation not described in text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:00:17 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brunnmuller-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:02:58 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Glowinski-1999">
<DESCRIPTION>
<P>Quote: "This...randomized...study was carried out in two parallel groups"</P>
<P>Comment: Method of sequence generation not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:08:54 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hardin-1979">
<DESCRIPTION>
<P>Quote: "Sets of [identical] capsules of each of these 6 agents were prepared in advance by a hospital pharmacist, varying the sequence of the agents from set to set." </P>
<P>Comment: Probably adequate, although method of sequence generation not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:12:25 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hill-1970">
<DESCRIPTION>
<P>Order of administration randomized by latin square design in sets of four patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:41:00 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huskisson-1974">
<DESCRIPTION>
<P>Quote: "Treatment order was randomized and balanced so far as possible".</P>
<P>Comment: Not clear that treatment allocation was random.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:18:36 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2006">
<DESCRIPTION>
<P>Quote: "Subjects were randomized in a 3:1 ratio..."</P>
<P>Comment: Method of randomization unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:30:25 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moran-1991">
<DESCRIPTION>
<P>Quote: "...patients were randomly allocated..."</P>
<P>Comment: Method of randomization unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:21:13 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nuki-1973">
<DESCRIPTION>
<P>Quote: "Patients were randomly allocated to initial pentazocine or placebo treatment periods". </P>
<P>Comment: method of randomization unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:27:45 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saarialho-1988">
<DESCRIPTION>
<P>Quote: "The trial comprised four randomized double-blind crossover treatment periods started at two-week intervals". </P>
<P>Comment: randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-09-17 23:43:01 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:44:06 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bedi-1969">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-28 16:01:44 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boureau-1991">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:00:24 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brunnmuller-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:03:11 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Glowinski-1999">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:09:14 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hardin-1979">
<DESCRIPTION>
<P>Pharmacy-based sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:39:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hill-1970">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:41:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huskisson-1974">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:41:46 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2006">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:42:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moran-1991">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:43:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nuki-1973">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:27:53 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saarialho-1988">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-09-18 16:00:48 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-17 23:36:15 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bedi-1969">
<DESCRIPTION>
<P>Quote: "Matching tablets...were used", "The trial...was double-blind".</P>
<P>Comment: No further detail given; maintenance of blind doubtful.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-28 16:02:26 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boureau-1991">
<DESCRIPTION>
<P>Quote: "...double-blind study versus placebo..."</P>
<P>Comment: Blinding method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 17:01:24 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brunnmuller-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 17:03:30 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glowinski-1999">
<DESCRIPTION>
<P>Double-dummy method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-17 23:38:43 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hardin-1979">
<DESCRIPTION>
<P>Quote: "All doses of all test agents were standard hospital preparations and were concealed in large opaque gelatin capsules".</P>
<P>Quote: "Records of the sequence of the drugs in each set were kept by the pharmacist and were not available to the patients' physicians until completion of the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 17:13:44 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hill-1970">
<DESCRIPTION>
<P>Quote: "&#8230;the trial was conducted under double-blind conditions". </P>
<P>Quote: "All treatments appeared to be identical and were presented to patients in the form of four white tablets". </P>
<P>Comment: unclear whether study personnel were adequately blinded to treatment allocation.</P>
<P>Comment: Single outcome assessor (lead author on study); unclear whether blinding was maintained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-01-10 16:14:05 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huskisson-1974">
<DESCRIPTION>
<P>Quote: "The double-placebo method was used to ensure that the trial was double-blind&#8230;"</P>
<P>Comment: Method of blinding of study personnel and outcome assessors is not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-02 18:17:46 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lee-2006">
<DESCRIPTION>
<P>Quote: "All subjects, investigators and clinical personnel were blinded to treatment assignment until the trial was completed&#8230;".</P>
<P>Comment: Matching placebo used. Blinding probably adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-18 16:00:48 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moran-1991">
<DESCRIPTION>
<P>High rate of adverse effects and drop-outs suggests blinding may not have been adequately maintained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 17:22:35 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nuki-1973">
<DESCRIPTION>
<P>Quote: "The trial was of the double-blind cross-over type"</P>
<P>Quote: "identical placebo tablets"</P>
<P>Comment: Blinding of participants probably adequate; blinding of study personnel and outcome assessors unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 17:28:43 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saarialho-1988">
<DESCRIPTION>
<P>Quote: study drugs were given in "identical gelatin capsules".</P>
<P>Comment: Blinding of participants probably adequate; blinding of study personnel and outcome assessors unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-09-17 23:36:17 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-09-17 23:36:17 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bedi-1969">
<DESCRIPTION>
<P>3/51 dropped out due to AE and were excluded from data analysis. A further 3/51 were lost to follow-up and also excluded from analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-28 16:04:18 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boureau-1991">
<DESCRIPTION>
<P>One subject randomized to placebo group excluded from efficacy analysis due to insufficient pain at baseline, but included in safety analysis.</P>
<P>Efficacy data for dropouts imputed by LOCF. No information given on timing of dropouts or dropouts from active treatment group. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-02 18:16:55 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brunnmuller-2004">
<DESCRIPTION>
<P>One participant who withdrew immediately after randomization but before any treatment was received did not provide any data and was not included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-01-08 17:35:09 +1100" MODIFIED_BY="Bethan L Richards" RESULT="NO" STUDY_ID="STD-Glowinski-1999">
<DESCRIPTION>
<P>Quote: "In the event of withdrawal, the last recorded score was extrapolated to D(ay) 7."</P>
<P>Comment: End of study assessments (primary outcome) not available for 2 withdrawals from paracetamol/codeine group due to adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-09-06 17:32:15 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hardin-1979">
<DESCRIPTION>
<P>Quote: "Thirty subjects took and evaluated their responses to all 6 test agents, and only these 30 responses were considered in analyzing the data".</P>
<P>Comment: Unclear whether there were other subjects who commenced treatment but did not complete the protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-30 17:14:14 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hill-1970">
<DESCRIPTION>
<P>Data collected for 40 completers; unclear whether other subjects commenced the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-30 17:17:39 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huskisson-1974">
<DESCRIPTION>
<P>78 patients were randomized, but only 67 were included in the analysis. No information provided on the remaining subjects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-30 17:19:34 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lee-2006">
<DESCRIPTION>
<P>277 individuals randomized. Text states that 267 subjects for whom at least one efficacy measurement was available were analysed (ITT) but only 248 included in the primary efficacy analysis. Missing data imputed by LOCF, although BOCF may have been more appropriate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-30 17:31:15 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moran-1991">
<DESCRIPTION>
<P>High drop-out rate. Initial cross-over design but data only analysed for first period. Completers only were analysed for efficacy outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-30 17:26:53 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nuki-1973">
<DESCRIPTION>
<P>Five out of forty participants failed to complete the study and were not included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-30 17:29:00 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saarialho-1988">
<DESCRIPTION>
<P>1/16 subjects dropped out "due to reasons unrelated to the trial" and was not included in data analysis. No further information on missing data provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-09-17 23:38:49 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:36:20 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bedi-1969">
<DESCRIPTION>
<P>Insufficient information provided regarding adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-28 16:04:38 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boureau-1991">
<DESCRIPTION>
<P>Daily pain VAS scores not reported in text.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:37:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brunnmuller-2004">
<DESCRIPTION>
<P>Insufficient information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:07:28 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Glowinski-1999">
<DESCRIPTION>
<P>Quote: "&#8230;the principal criterion of efficacy was the assessment by the patient and physician of the overall efficacy of the 7-day treatment using a verbal 5-point scale".</P>
<P>Comment 1: One set of efficacy data presented; unclear whether patient or physician or combined scores. </P>
<P>Comment 2: Other outcome measures not clearly reported in results: Patient-reported 5-point verbal pain scale at end of trial, duration of morning stiffness.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:38:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hardin-1979">
<DESCRIPTION>
<P>Three outcome measures listed in methods and all reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:14:28 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hill-1970">
<DESCRIPTION>
<P>Reported outcomes not clearly specified in methods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 16:53:12 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huskisson-1974">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 17:03:45 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lee-2006">
<DESCRIPTION>
<P>One of the secondary outcome measures specified in the methods section ("pain intensity at the second visit") was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 17:04:38 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moran-1991">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 17:05:30 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nuki-1973">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-06 17:06:26 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saarialho-1988">
<DESCRIPTION>
<P>Insufficient information provided, although it appears that only one pain outcome measure was planned, and was reported in full.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-09-17 23:43:10 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:36:26 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bedi-1969">
<DESCRIPTION>
<P>No washout period. Potential for carry-over effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 17:40:12 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boureau-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:37:51 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brunnmuller-2004">
<DESCRIPTION>
<P>Intervention and control groups had significantly different disease duration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-07 12:50:14 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glowinski-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-07 12:39:33 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hardin-1979">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-07 12:36:10 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hill-1970">
<DESCRIPTION>
<P>An initial dose of placebo was given to all participants and those who 'responded' to placebo were excluded from randomization into the trial. Judgement of 'placebo responder' was made subjectively by the investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-07 12:33:18 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huskisson-1974">
<DESCRIPTION>
<P>Three separate trials reported. It is unclear whether participants could be recruited into more than one trial. Not all participants appeared to complete each trial, but reasons not given. No mention of adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-22 13:45:21 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lee-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:42:21 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moran-1991">
<DESCRIPTION>
<P>Planned as cross-over trial but only the results of phase I were analysed due to unexpected number of withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-17 23:43:10 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nuki-1973">
<DESCRIPTION>
<P>No washout period. Potential for carry-over effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-07 12:06:05 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saarialho-1988">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-09-18 16:03:20 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-09-18 16:03:20 +1000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-08-31 22:51:47 +1000" MODIFIED_BY="Grade Profiler">Opioids for rheumatoid arthritis pain</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Opioids for rheumatoid arthritis pain</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with rheumatoid arthritis pain<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Opioids<SUP>1</SUP>
<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Opioids</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient reported global impression of clinical change (PGIC) 'good' or 'very good'</B>
<BR/>PGIC scale: Very poor, Poor, No change, Good, Very good.<BR/>Follow-up: 1-6 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>398 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>573 per 1000</B>
<BR/>(410 to 808)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.44 </B>
<BR/>(1.03 to 2.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>324<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute risk difference = 18% (1% to 41%). Relative percent change = 44% (3% to 103%). NNT = 6 (3 to 84)<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Withdrawal due to inadequate analgesia</B>
<BR/>Follow-up: median 1.5 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>78 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>64 per 1000</B>
<BR/>(27 to 157)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.34 to 2.01)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>345<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not statistically significant<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Functional status (HAQ)</B>
<BR/>HAQ. Scale from: 0 to 3.<BR/>Follow-up: 1-2 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Functional status (HAQ) in the intervention groups was<BR/>
<B>0.1 lower</B>
<BR/>(0.33 lower to 0.13 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>243<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>HAQ only reported in two studies (of duration one week and two weeks).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Withdrawal due to adverse events</B>
<BR/>Follow-up: 1-6 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>53 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>142 per 1000</B>
<BR/>(28 to 729)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.67 </B>
<BR/>(0.52 to 13.75)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>331<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not statistically significant<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Participants reporting adverse events</B>
<BR/>Follow-up: 1-6 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>209 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>508 per 1000</B>
<BR/>(379 to 634)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 3.90 </B>
<BR/>(2.31 to 6.56)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>371<BR/>(4 studies<SUP>8</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute risk difference = 30% (17% to 42%). Relative percent change = 143% (81% to 203%). NNTH = 4 (3 to 6)<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious adverse events</B>
<BR/>Follow-up: 1 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>317<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>9,10</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Two studies reported serious adverse events. In each study, one participant in the opioid group experienced an SAE. There were no deaths.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> There was heterogeneity in the choice of opioid and the use of an adjunctive non-opioid analgesic. 10 of the 11 included studies used a weak opioid. Oral morphine was the only strong opioid used.<BR/>
<SUP>2</SUP> Included studies were potentially biased due to unclear or inadequate sequence generation, allocation concealment and management of incomplete data.<BR/>
<SUP>3</SUP> Substantial secular changes in the management of rheumatoid arthritis may limit the applicability of the findings to patients in the current era.<BR/>
<SUP>4</SUP> Note: Number needed to treat (NNT) = n/a when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (http://nntonline.net/visualrx/).<BR/>
<SUP>5</SUP> Only two studies reported this outcome; Moran 1991 was at high risk of bias due to a change in design resulting from an unexpectedly high number of withdrawals. Lee 2006 reported HAQ scores for only 223 of the 267 participants; no explanation was provided.<BR/>
<SUP>6</SUP> Adequate data for this outcome was only available for three trials, none of which clearly described the randomization or allocation concealment methods.<BR/>
<SUP>7</SUP> Data for this outcome was available from four trials, none of which clearly described the randomization or allocation concealment methods.<BR/>
<SUP>8</SUP> One of the four trials was cross-over design<BR/>
<SUP>9</SUP> Bedi 1969 at high risk of bias due to inadequate randomization, potential for carry-over effects, and incomplete outcome data. Single SAE (upper GI bleed) occurred in the combination treatment group in phase I.<BR/>
<SUP>10</SUP> Only two SAEs were reported in the 11 included studies. Only one study (Lee 2006) pre-specified SAEs as an outcome measure. 9 of the 11 studies reported adverse events.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-09-18 16:28:18 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-09-18 16:27:17 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Opioid versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2011-01-08 13:34:35 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="40.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="28" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain VAS</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.01" MODIFIED="2010-12-22 16:19:12 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Morphine, measured at 2 weeks</NAME>
<CONT_DATA CI_END="24.686135397547226" CI_START="-13.686135397547226" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="59.8" MEAN_2="54.3" MODIFIED="2010-12-22 16:18:39 +1100" MODIFIED_BY="[Empty name]" ORDER="51" SD_1="16.0" SD_2="26.5" SE="9.789024466207039" STUDY_ID="STD-Moran-1991" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.02" MODIFIED="2010-12-22 16:19:12 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Morphine, measured at 4 weeks</NAME>
<CONT_DATA CI_END="-7.348003769169759" CI_START="-38.051996230830234" EFFECT_SIZE="-22.699999999999996" ESTIMABLE="YES" MEAN_1="49.6" MEAN_2="72.3" MODIFIED="2010-12-19 11:41:00 +1100" MODIFIED_BY="[Empty name]" ORDER="27" SD_1="13.4" SD_2="16.9" SE="7.832795067626152" STUDY_ID="STD-Moran-1991" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.03" MODIFIED="2011-01-02 12:53:10 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Tilidine/naloxone, measured at 6 weeks</NAME>
<CONT_DATA CI_END="-0.9037936342313522" CI_START="-3.9362063657686477" EFFECT_SIZE="-2.42" ESTIMABLE="YES" MEAN_1="4.23" MEAN_2="6.65" MODIFIED="2011-01-02 12:53:10 +1100" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="1.37" SD_2="1.85" SE="0.773588891289988" STUDY_ID="STD-Brunnmuller-2004" TOTAL_1="11" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2011-01-08 13:35:17 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="182" TOTAL_2="65" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean daily pain intensity</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2010-12-19 11:33:41 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="182" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Tramadol/paracetamol</NAME>
<CONT_DATA CI_END="-1.6126228561995397" CI_START="-11.547377143800471" EFFECT_SIZE="-6.580000000000005" ESTIMABLE="YES" MEAN_1="47.23" MEAN_2="53.81" MODIFIED="2010-12-19 11:33:41 +1100" MODIFIED_BY="[Empty name]" ORDER="26" SD_1="19.96" SD_2="16.59" SE="2.534422664386949" STUDY_ID="STD-Lee-2006" TOTAL_1="182" TOTAL_2="65" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2011-01-08 13:35:27 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="183" TOTAL_2="65" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean daily pain relief (maximum score = 4, negative score = pain worse)</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours opioid</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.01" MODIFIED="2010-12-22 16:59:44 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="183" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Tramadol/paracetamol</NAME>
<CONT_DATA CI_END="0.49334743126533587" CI_START="0.026652568734664123" EFFECT_SIZE="0.26" ESTIMABLE="YES" MEAN_1="1.04" MEAN_2="0.78" MODIFIED="2010-12-22 16:59:44 +1100" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="0.89" SD_2="0.8" SE="0.11905699957037509" STUDY_ID="STD-Lee-2006" TOTAL_1="183" TOTAL_2="65" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-01-10 15:22:53 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Pain relief of 50% or better</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-12-08 23:40:56 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Codeine/paracetamol</NAME>
<DICH_DATA CI_END="5.245324460919454" CI_START="0.9910540403612649" EFFECT_SIZE="2.28" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.7197723575874654" LOG_CI_START="-0.0039026635865579383" LOG_EFFECT_SIZE="0.35793484700045375" MODIFIED="2010-12-08 23:40:56 +1100" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.4250902896867499" STUDY_ID="STD-Boureau-1991" TOTAL_1="20" TOTAL_2="19" VAR="0.18070175438596492" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0879157378867483" CI_END="2.009475333669474" CI_START="0.337239622483955" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8232099992817828" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.30308267959151036" LOG_CI_START="-0.47206140553240056" LOG_EFFECT_SIZE="-0.08448936297044508" METHOD="MH" MODIFIED="2011-01-08 13:36:09 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5543614089632016" P_Q="0.5758619900958472" P_Z="0.6691860610521234" Q="1.9833869346433814" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="103" WEIGHT="99.99999999999999" Z="0.42726536053573316">
<NAME>Withdrawal due to inadequate analgesia</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.727518033173625" CI_START="0.009733334303263463" DF="0" EFFECT_SIZE="0.19047619047619047" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.571419753181733" LOG_CI_START="-2.0117383599936467" LOG_EFFECT_SIZE="-0.7201593034059569" MODIFIED="2010-12-08 23:01:58 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.27446507861628766" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="9.004568271406834" Z="1.0928377094749666">
<NAME>Codeine/paracetamol</NAME>
<DICH_DATA CI_END="3.727518033173625" CI_START="0.009733334303263463" EFFECT_SIZE="0.19047619047619047" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.571419753181733" LOG_CI_START="-2.0117383599936467" LOG_EFFECT_SIZE="-0.7201593034059569" MODIFIED="2010-12-08 22:58:58 +1100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="1.5173598625181017" STUDY_ID="STD-Boureau-1991" TOTAL_1="20" TOTAL_2="19" VAR="2.3023809523809526" WEIGHT="9.004568271406834"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.12502868001892" CI_START="0.12822350118358078" DF="0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.6154269724085276" LOG_CI_START="-0.8920323687410906" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2010-12-08 23:05:51 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7191193753329441" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="26.44074332724762" Z="0.359635978193486">
<NAME>Tilidine/naloxone</NAME>
<DICH_DATA CI_END="4.12502868001892" CI_START="0.12822350118358078" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6154269724085276" LOG_CI_START="-0.8920323687410906" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2010-12-08 23:05:51 +1100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.8854890790353708" STUDY_ID="STD-Brunnmuller-2004" TOTAL_1="11" TOTAL_2="8" VAR="0.7840909090909091" WEIGHT="26.44074332724762"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.176739530824377" CI_START="0.020827610264392168" DF="0" EFFECT_SIZE="0.32835820895522394" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.7140563138766846" LOG_CI_START="-1.6813605576339248" LOG_EFFECT_SIZE="-0.4836521218786201" MODIFIED="2010-12-08 23:03:01 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4286744368227279" STUDIES="1" TAU2="0.0" TOTAL_1="201" TOTAL_2="66" WEIGHT="10.471349777429959" Z="0.7914620216652957">
<NAME>Tramadol/paracetamol</NAME>
<DICH_DATA CI_END="5.176739530824377" CI_START="0.020827610264392168" EFFECT_SIZE="0.3283582089552239" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.7140563138766846" LOG_CI_START="-1.6813605576339248" LOG_EFFECT_SIZE="-0.48365212187862017" MODIFIED="2010-12-08 23:03:01 +1100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="1.4070797278300813" STUDY_ID="STD-Lee-2006" TOTAL_1="201" TOTAL_2="66" VAR="1.9798733604703753" WEIGHT="10.471349777429959"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.4869472965209996" CI_START="0.396210978264932" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="0.6519509683597887" LOG_CI_START="-0.40207349514318896" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2010-12-08 23:04:29 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6421832215115779" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="54.08333862391558" Z="0.4646484640638742">
<NAME>Morphine</NAME>
<DICH_DATA CI_END="4.4869472965209996" CI_START="0.396210978264932" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6519509683597887" LOG_CI_START="-0.40207349514318896" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2010-12-08 23:04:29 +1100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Moran-1991" TOTAL_1="10" TOTAL_2="10" VAR="0.3833333333333333" WEIGHT="54.08333862391558"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3853686000876264" CI_END="2.026667338869994" CI_START="1.0279570493739933" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.443373471325922" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="37" I2="16.155515758590514" I2_Q="16.095660852529065" ID="CMP-001.06" LOG_CI_END="0.3067824685995268" LOG_CI_START="0.01197496912467256" LOG_EFFECT_SIZE="0.1593787188620997" METHOD="MH" MODIFIED="2011-09-18 16:27:17 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3034057965380964" P_Q="0.30366405151385156" P_Z="0.034074415091065235" Q="2.3836669477662937" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.018947641142696564" TOTALS="YES" TOTAL_1="231" TOTAL_2="93" WEIGHT="100.0" Z="2.1191899760236215">
<NAME>Patient reported global impression of clinical change (PGIC) 'good' or 'very good'</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours opioid</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6252927904952146" CI_START="0.45331425467542275" DF="0" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.4191777459154762" LOG_CI_START="-0.3436006241366767" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2011-09-18 16:27:17 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8460224884027266" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="13.649347446983947" Z="0.1941959061208263">
<NAME>Tilidine/naloxone</NAME>
<DICH_DATA CI_END="2.6252927904952146" CI_START="0.45331425467542275" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.4191777459154762" LOG_CI_START="-0.3436006241366767" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2010-12-19 09:41:47 +1100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.4480597903824619" STUDY_ID="STD-Brunnmuller-2004" TOTAL_1="11" TOTAL_2="8" VAR="0.2007575757575757" WEIGHT="13.649347446983947"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8192238556442915" CI_START="0.9659064841008573" DF="0" EFFECT_SIZE="1.3255942509673853" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="27" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.2598861423231832" LOG_CI_START="-0.015064918517151008" LOG_EFFECT_SIZE="0.12241061190301611" MODIFIED="2010-12-19 09:49:22 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.08095247255567908" STUDIES="1" TAU2="0.0" TOTAL_1="201" TOTAL_2="66" WEIGHT="66.59285609082626" Z="1.7451861427422888">
<NAME>Tramadol/paracetamol</NAME>
<DICH_DATA CI_END="1.8192238556442915" CI_START="0.9659064841008573" EFFECT_SIZE="1.3255942509673853" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="27" LOG_CI_END="0.2598861423231832" LOG_CI_START="-0.015064918517151008" LOG_EFFECT_SIZE="0.12241061190301611" MODIFIED="2010-12-19 09:49:22 +1100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.1615076141673139" STUDY_ID="STD-Lee-2006" TOTAL_1="201" TOTAL_2="66" VAR="0.026084709434017937" WEIGHT="66.59285609082626"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.766579646233973" CI_START="1.1422119944530973" DF="0" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.6782068541778385" LOG_CI_START="0.05774671641135026" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2011-01-07 21:56:47 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.020082935995098982" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="19.757796462189784" Z="2.3247947851104875">
<NAME>Codeine/paracetamol</NAME>
<DICH_DATA CI_END="4.766579646233973" CI_START="1.1422119944530973" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.6782068541778385" LOG_CI_START="0.05774671641135026" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2011-01-07 21:56:47 +1100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.3644613562512509" STUDY_ID="STD-Boureau-1991" TOTAL_1="19" TOTAL_2="19" VAR="0.13283208020050125" WEIGHT="19.757796462189784"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-01-08 13:36:58 +1100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Desire to resume treatment</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours opioid</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="7" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-12-22 17:06:10 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Codeine/paracetamol</NAME>
<DICH_DATA CI_END="3.657462973559336" CI_START="0.987022979069793" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.5631799382258489" LOG_CI_START="-0.005672736320191025" LOG_EFFECT_SIZE="0.2787536009528289" MODIFIED="2010-12-22 17:06:10 +1100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.33414687689449657" STUDY_ID="STD-Boureau-1991" TOTAL_1="20" TOTAL_2="19" VAR="0.11165413533834584" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.4329008616661922" CI_END="0.1318432930529414" CI_START="-0.33282162925627645" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10048916810166751" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2010-12-23 22:50:26 +1100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.5105689830316027" P_Q="0.5105689830316027" P_Z="0.3965884760187577" Q="0.4329008616661922" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="170" TOTAL_2="73" UNITS="" WEIGHT="100.0" Z="0.8477297977943469">
<NAME>Functional status (HAQ)</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.17945405688814872" CI_START="-0.3194540568881489" DF="0" EFFECT_SIZE="-0.07000000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" MODIFIED="2010-12-19 10:05:07 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5823255690689239" STUDIES="1" TAU2="0.0" TOTAL_1="160" TOTAL_2="63" WEIGHT="86.74383995579676" Z="0.5499909707995693">
<NAME>Tramadol/paracetamol</NAME>
<CONT_DATA CI_END="0.17945405688814872" CI_START="-0.3194540568881489" EFFECT_SIZE="-0.07000000000000006" ESTIMABLE="YES" MEAN_1="1.02" MEAN_2="1.09" MODIFIED="2010-12-19 10:05:07 +1100" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="0.87" SD_2="0.85" SE="0.12727481670878166" STUDY_ID="STD-Lee-2006" TOTAL_1="160" TOTAL_2="63" WEIGHT="86.74383995579676"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.33811804158288583" CI_START="-0.9381180415828855" DF="0" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" MODIFIED="2010-12-23 22:50:26 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3568193677273479" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="13.256160044203249" Z="0.9214426752509262">
<NAME>Morphine</NAME>
<CONT_DATA CI_END="0.33811804158288583" CI_START="-0.9381180415828855" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.4" MODIFIED="2010-12-23 22:50:26 +1100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="0.9" SD_2="0.5" SE="0.32557641192199416" STUDY_ID="STD-Moran-1991" TOTAL_1="10" TOTAL_2="10" WEIGHT="13.256160044203249"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="1.442541131007138" CI_END="6.563347458875244" CI_START="2.3129099444873584" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="3.8962073362127927" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.8171253961017931" LOG_CI_START="0.3641587234002774" LOG_DATA="YES" LOG_EFFECT_SIZE="0.5906420597510352" MODIFIED="2011-03-28 23:42:38 +1100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6955938654950542" P_Q="0.6955938654950542" P_Z="3.1985305406084143E-7" Q="1.442541131007138" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="236" TOTAL_2="95" WEIGHT="100.0" Z="5.1113569038639355">
<NAME>Participants reporting adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="8.545938336800658" CI_START="0.6354282348783504" DF="0" EFFECT_SIZE="2.3303069567618055" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.9317597548416006" LOG_CI_START="-0.1969334914612985" LOG_EFFECT_SIZE="0.36741313169015105" MODIFIED="2011-03-28 23:38:36 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2019491466288369" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.105738619517766" Z="1.2760180995475112">
<NAME>Codeine/paracetamol</NAME>
<IV_DATA CI_END="8.545938336800658" CI_START="0.6354282348783504" EFFECT_SIZE="2.3303069567618055" ESTIMABLE="YES" ESTIMATE="0.846" LOG_CI_END="0.9317597548416006" LOG_CI_START="-0.1969334914612985" LOG_EFFECT_SIZE="0.36741313169015105" MODIFIED="2011-03-28 23:38:36 +1100" MODIFIED_BY="[Empty name]" ORDER="39" SE="0.663" STUDY_ID="STD-Boureau-1991" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.105738619517766"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="12.845657562228215" CI_START="0.31129762796718463" DF="0" EFFECT_SIZE="1.9997056605411638" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="1.1087563404698517" LOG_CI_START="-0.5068241885519448" LOG_EFFECT_SIZE="0.30096607595895347" MODIFIED="2011-03-28 23:38:36 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4652420593245786" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="7.860954428479211" Z="0.7302423603793466">
<NAME>Tilidine/naloxone</NAME>
<IV_DATA CI_END="12.845657562228215" CI_START="0.31129762796718463" EFFECT_SIZE="1.9997056605411638" ESTIMABLE="YES" ESTIMATE="0.693" LOG_CI_END="1.1087563404698517" LOG_CI_START="-0.5068241885519448" LOG_EFFECT_SIZE="0.30096607595895347" MODIFIED="2011-03-28 23:38:36 +1100" MODIFIED_BY="[Empty name]" ORDER="38" SE="0.949" STUDY_ID="STD-Brunnmuller-2004" TOTAL_1="11" TOTAL_2="8" WEIGHT="7.860954428479211"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="8.90798672321435" CI_START="2.481967868875163" DF="0" EFFECT_SIZE="4.702056658887105" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.949779561074277" LOG_CI_START="0.39479615489819087" LOG_EFFECT_SIZE="0.6722878579862338" MODIFIED="2011-03-28 23:38:36 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="2.0496507505588896E-6" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="67" WEIGHT="66.61507225754454" Z="4.748466257668712">
<NAME>Tramadol/paracetamol</NAME>
<IV_DATA CI_END="8.90798672321435" CI_START="2.481967868875163" EFFECT_SIZE="4.702056658887105" ESTIMABLE="YES" ESTIMATE="1.548" LOG_CI_END="0.949779561074277" LOG_CI_START="0.39479615489819087" LOG_EFFECT_SIZE="0.6722878579862338" MODIFIED="2011-03-28 23:38:36 +1100" MODIFIED_BY="[Empty name]" ORDER="40" SE="0.326" STUDY_ID="STD-Lee-2006" TOTAL_1="205" TOTAL_2="67" WEIGHT="66.61507225754454"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="23.69558572813064" CI_START="0.791924852721938" DF="0" EFFECT_SIZE="4.331872948034132" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="1.374667448437447" LOG_CI_START="-0.10131602749711281" LOG_EFFECT_SIZE="0.6366757104701672" MODIFIED="2011-03-28 23:38:36 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.09085817269175302" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.418234694458487" Z="1.6908881199538641">
<NAME>Pentazocine</NAME>
<IV_DATA CI_END="23.695585728130652" CI_START="0.7919248527219378" EFFECT_SIZE="4.331872948034132" ESTIMABLE="YES" ESTIMATE="1.466" LOG_CI_END="1.3746674484374473" LOG_CI_START="-0.10131602749711294" LOG_EFFECT_SIZE="0.6366757104701672" MODIFIED="2011-03-28 23:38:36 +1100" MODIFIED_BY="[Empty name]" ORDER="41" SE="0.867" STUDY_ID="STD-Nuki-1973" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.418234694458487"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-01-08 13:37:21 +1100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="227" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-07 13:49:47 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="67" WEIGHT="0.0" Z="0.0">
<NAME>Tramadol/paracetamol</NAME>
<DICH_DATA CI_END="24.024919990794615" CI_START="0.04081914879377387" EFFECT_SIZE="0.9902912621359223" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3806619500298958" LOG_CI_START="-1.3891360559164052" LOG_EFFECT_SIZE="-0.004237052943254642" MODIFIED="2011-01-07 13:49:47 +1100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="1.6269930594141102" STUDY_ID="STD-Lee-2006" TOTAL_1="205" TOTAL_2="67" VAR="2.6471064153816863" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-01-07 13:52:16 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Dextropropoxyphene plus aspirin versus aspirin alone</NAME>
<DICH_DATA CI_END="72.98606354122126" CI_START="0.13426702924773704" EFFECT_SIZE="3.130434782608696" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8632399408743792" LOG_CI_START="-0.8720306200470282" LOG_EFFECT_SIZE="0.49560466041367557" MODIFIED="2011-01-07 13:52:16 +1100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="1.6067114672928786" STUDY_ID="STD-Bedi-1969" TOTAL_1="22" TOTAL_2="23" VAR="2.5815217391304346" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.634361465194448" CI_END="13.745629107168988" CI_START="0.5168098300698998" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6653097836986737" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="5" I2="56.8441086216376" I2_Q="53.85751704286696" ID="CMP-001.11" LOG_CI_END="1.1381646213362449" LOG_CI_START="-0.286669234361825" LOG_EFFECT_SIZE="0.4257476934872099" METHOD="MH" MODIFIED="2011-01-07 13:50:38 +1100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.09855120771323667" P_Q="0.11449781236618328" P_Z="0.24148037623274698" Q="4.33440047397975" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.1716169608754525" TOTALS="YES" TOTAL_1="236" TOTAL_2="95" WEIGHT="100.0" Z="1.1712946634428572">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5713646359076354" CI_START="0.12444667228203433" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.5528341938718855" LOG_CI_START="-0.905016711983248" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-12-09 09:51:02 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6358698851622282" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="36.77223337742055" Z="0.4734812378348157">
<NAME>Codeine/paracetamol</NAME>
<DICH_DATA CI_END="3.5713646359076354" CI_START="0.12444667228203433" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5528341938718855" LOG_CI_START="-0.905016711983248" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-12-09 09:51:02 +1100" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Boureau-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="36.77223337742055"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="89.35130018847644" CI_START="0.3084734071228962" DF="0" EFFECT_SIZE="5.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="1.9511008764899271" LOG_CI_START="-0.5107822696780132" LOG_EFFECT_SIZE="0.7201593034059569" MODIFIED="2010-12-09 09:51:56 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.25151720531633714" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="8" WEIGHT="21.46849738856254" Z="1.146672050624488">
<NAME>Tilidine/naloxone</NAME>
<DICH_DATA CI_END="89.35130018847644" CI_START="0.3084734071228962" EFFECT_SIZE="5.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9511008764899271" LOG_CI_START="-0.5107822696780132" LOG_EFFECT_SIZE="0.7201593034059569" MODIFIED="2010-12-09 09:51:56 +1100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="1.4461223465771633" STUDY_ID="STD-Brunnmuller-2004" TOTAL_1="11" TOTAL_2="8" VAR="2.091269841269841" WEIGHT="21.46849738856254"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.746963494433977E-32" CI_END="25.689126531255706" CI_START="1.581108844867579" DF="0" EFFECT_SIZE="6.373170731707317" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="2" I2="100.0" ID="CMP-001.11.03" LOG_CI_END="1.4097493378551045" LOG_CI_START="0.1989617681600758" LOG_EFFECT_SIZE="0.8043555530075901" MODIFIED="2010-12-09 09:53:37 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.009211500565079807" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="67" WEIGHT="41.75926923401691" Z="2.604103236799439">
<NAME>Tramadol/paracetamol</NAME>
<DICH_DATA CI_END="25.689126531255706" CI_START="1.581108844867579" EFFECT_SIZE="6.373170731707317" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="2" LOG_CI_END="1.4097493378551045" LOG_CI_START="0.1989617681600758" LOG_EFFECT_SIZE="0.8043555530075901" MODIFIED="2010-12-09 09:53:37 +1100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.7112226119339917" STUDY_ID="STD-Lee-2006" TOTAL_1="205" TOTAL_2="67" VAR="0.5058376037262095" WEIGHT="41.75926923401691"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-01-08 13:37:34 +1100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse event or inefficacy</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.1385431753839645" CI_START="0.7399946962534389" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6168474903390713" LOG_CI_START="-0.13077139296648244" LOG_EFFECT_SIZE="0.24303804868629442" MODIFIED="2010-12-18 23:25:26 +1100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.4391550328268399" STUDY_ID="STD-Moran-1991" TOTAL_1="10" TOTAL_2="10" VAR="0.1928571428571428" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-09-18 16:28:18 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Opioid versus NSAID</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.090369013108356" CI_START="-20.29036901310836" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.100000000000001" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2011-09-18 16:28:18 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.19280850588622223" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="28" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="1.30231564423548">
<NAME>Change in 100mm pain VAS</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.090369013108356" CI_START="-20.29036901310836" EFFECT_SIZE="-8.100000000000001" ESTIMABLE="YES" MEAN_1="-31.5" MEAN_2="-23.4" MODIFIED="2010-12-18 15:35:20 +1100" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="24.1" SD_2="23.2" SE="6.219690315365197" STUDY_ID="STD-Glowinski-1999" TOTAL_1="28" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8959841955611085" CI_START="0.6054687514595741" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.2778347128495119" LOG_CI_START="-0.21790826609462544" LOG_EFFECT_SIZE="0.029963223377443202" METHOD="MH" MODIFIED="2011-01-08 13:32:56 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.8127153317687199" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="28" TOTAL_2="30" WEIGHT="0.0" Z="0.2369245402349305">
<NAME>Global efficacy</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8959841955611085" CI_START="0.6054687514595741" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.2778347128495119" LOG_CI_START="-0.21790826609462544" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2010-12-18 15:33:45 +1100" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.2912018797991091" STUDY_ID="STD-Glowinski-1999" TOTAL_1="28" TOTAL_2="30" VAR="0.0847985347985348" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0173024308237273" CI_START="0.7432575489912849" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2244897959183674" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.3047710118428913" LOG_CI_START="-0.12886067113263142" LOG_EFFECT_SIZE="0.08795517035512998" METHOD="MH" MODIFIED="2011-01-08 13:31:24 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.4265588545333152" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="28" TOTAL_2="30" WEIGHT="0.0" Z="0.7950939606959977">
<NAME>Desire to resume treatment</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours opioid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0173024308237273" CI_START="0.7432575489912849" EFFECT_SIZE="1.2244897959183674" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.3047710118428913" LOG_CI_START="-0.12886067113263142" LOG_EFFECT_SIZE="0.08795517035512998" MODIFIED="2010-12-22 17:22:28 +1100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.2547173970912713" STUDY_ID="STD-Glowinski-1999" TOTAL_1="28" TOTAL_2="30" VAR="0.06488095238095237" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-22 17:23:16 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="28" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to inadequate analgesia</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-18 15:21:48 +1100" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.0" STUDY_ID="STD-Glowinski-1999" TOTAL_1="28" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1949495153554572" CI_START="0.5512655263982456" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.3414245357605148" LOG_CI_START="-0.2586391654440647" LOG_EFFECT_SIZE="0.04139268515822507" METHOD="MH" MODIFIED="2011-01-08 13:32:39 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.7868536691928749" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.27039853259135166">
<NAME>Participants reporting adverse events</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1949495153554572" CI_START="0.5512655263982456" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.3414245357605148" LOG_CI_START="-0.2586391654440647" LOG_EFFECT_SIZE="0.04139268515822507" MODIFIED="2010-12-09 10:40:13 +1100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.3524803884507963" STUDY_ID="STD-Glowinski-1999" TOTAL_1="30" TOTAL_2="30" VAR="0.12424242424242427" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="27.234348125670888" CI_START="0.3304650421030884" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="1.4351169845729046" LOG_CI_START="-0.4808744751335798" LOG_EFFECT_SIZE="0.4771212547196624" METHOD="MH" MODIFIED="2011-01-08 13:31:58 +1100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.3289937987651492" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.9761426344273542">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="27.234348125670888" CI_START="0.3304650421030884" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4351169845729046" LOG_CI_START="-0.4808744751335798" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-12-09 10:28:12 +1100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="1.1254628677422753" STUDY_ID="STD-Glowinski-1999" TOTAL_1="30" TOTAL_2="30" VAR="1.2666666666666664" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-09-18 16:28:49 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-09-05 11:43:26 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZAAAAPvCAYAAADtVJjxAAAtwklEQVR42u3djY6sPLJm4b7/m/5G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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-09-18 16:00:49 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATAAAAJkCAIAAAAZburYAAAdLElEQVR42u3dv44cxxHH8QOcOLiA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</FILE>
</FIGURE>
<FIGURE FILENAME="NEAR without Moran 2.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-09-18 16:28:49 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Net efficacy adjusted for risk</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2wAAAIOCAYAAADEJ460AACAAElEQVR42uydB7xdRbX/aaEKUUBU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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-04-14 22:53:26 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-04-13 16:54:17 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-04-13 16:54:10 +1000" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-04-13 16:54:17 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>exp arthritis, rheumatoid/</LI>
<LI>(felty$ adj2 syndrome).tw.</LI>
<LI>(caplan$ adj2 syndrome).tw.</LI>
<LI>rheumatoid nodule.tw.</LI>
<LI>(sjogren$ adj2 syndrome).tw.</LI>
<LI>(sicca adj2 syndrome).tw.</LI>
<LI>still$ disease.tw.</LI>
<LI>((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit$ or artrit$ or diseas$ or condition$ or nodule$)).tw.</LI>
<LI>or/1-8</LI>
<LI>randomized controlled trial.pt.</LI>
<LI>controlled clinical trial.pt.</LI>
<LI>randomized.ab.</LI>
<LI>placebo.ab.</LI>
<LI>drug therapy.fs.</LI>
<LI>randomly.ab.</LI>
<LI>trial.ab.</LI>
<LI>groups.ab.</LI>
<LI>10 or 11 or 12 or 13 or 14 or 15 or 16 or 17</LI>
<LI>exp animals/ not humans.sh.</LI>
<LI>18 not 19</LI>
<LI>exp Analgesics, Opioid/</LI>
<LI>exp narcotics/</LI>
<LI>exp morphine derivatives/</LI>
<LI>narcotic$.mp.</LI>
<LI>opiate$.mp.</LI>
<LI>opioid$.mp.</LI>
<LI>acemethadone.mp.</LI>
<LI>acetylmethadol.mp.</LI>
<LI>alfentanil.mp.</LI>
<LI>alphaprodine.mp.</LI>
<LI>anileridine.mp.</LI>
<LI>benzomorphan$.mp.</LI>
<LI>buprenorphine.mp.</LI>
<LI>butorphanol.mp.</LI>
<LI>carfentanil.mp.</LI>
<LI>codeine.mp.</LI>
<LI>dextromoramide.mp.</LI>
<LI>dextropropoxyphene.mp.</LI>
<LI>dezocine.mp.</LI>
<LI>diacetyl morphine.mp.</LI>
<LI>diamorphine.mp.</LI>
<LI>dihydroetorphine.mp.</LI>
<LI>dimepheptanol.mp.</LI>
<LI>dionine.mp.</LI>
<LI>diphenoxylate.mp.</LI>
<LI>diprenorphine.mp.</LI>
<LI>dihydrocodein$.mp.</LI>
<LI>dihydrohydroxycodeinone.mp.</LI>
<LI>dihydromorphine.mp.</LI>
<LI>dihydromorphinone.mp.</LI>
<LI>dipipanone.mp.</LI>
<LI>dynorphin.mp.</LI>
<LI>endomorphin.mp.</LI>
<LI>enkephalin$.mp.</LI>
<LI>eseroline.mp.</LI>
<LI>etorphine.mp.</LI>
<LI>ethylketocyclazocine.mp.</LI>
<LI>ethylmorphine.mp.</LI>
<LI>fenoperidine.mp.</LI>
<LI>fentanyl.mp.</LI>
<LI>heroin.mp.</LI>
<LI>hydrocodon$.mp.</LI>
<LI>hydromorphon$.mp.</LI>
<LI>hydroxycodeinone.mp.</LI>
<LI>isocodeine.mp.</LI>
<LI>isonipecain.mp.</LI>
<LI>isopromedol.mp.</LI>
<LI>kaolin-pectin.mp.</LI>
<LI>ketobemidone.mp.</LI>
<LI>levallorphan.mp.</LI>
<LI>levodroman.mp.</LI>
<LI>levomethadryl.mp.</LI>
<LI>levomethadyl.mp.</LI>
<LI>levorphan$.mp.</LI>
<LI>meperidine.mp.</LI>
<LI>meptazinol.mp.</LI>
<LI>methadol.mp.</LI>
<LI>methadone.mp.</LI>
<LI>methadyl acetate.mp.</LI>
<LI>morphia.mp.</LI>
<LI>morphine.mp.</LI>
<LI>methynaloxone.mp.</LI>
<LI>nalbuphine.mp.</LI>
<LI>nocistatin.mp.</LI>
<LI>opium.mp.</LI>
<LI>oxycodein$.mp.</LI>
<LI>oxycodone.mp.</LI>
<LI>oxymorph$.mp.</LI>
<LI>pantopon.mp.</LI>
<LI>papaveretum.mp.</LI>
<LI>paracymethadol.mp.</LI>
<LI>paregoric.mp.</LI>
<LI>pentazocine.mp.</LI>
<LI>pethidine.mp.</LI>
<LI>phenazocine.mp.</LI>
<LI>phenbenzorphan.mp.</LI>
<LI>phenethylazocine.mp.</LI>
<LI>phenoperidine.mp.</LI>
<LI>pirinitramide.mp.</LI>
<LI>promedol$.mp.</LI>
<LI>propoxyphene.mp.</LI>
<LI>protopine.mp.</LI>
<LI>pyrrolamidol.mp.</LI>
<LI>remifentanil.mp.</LI>
<LI>sufentanil.mp.</LI>
<LI>sufentanyl.mp.</LI>
<LI>talwin.mp.</LI>
<LI>tapentadol.mp.</LI>
<LI>thebaine.mp.</LI>
<LI>theocodin.mp.</LI>
<LI>tilidine.mp.</LI>
<LI>tramadol.mp.</LI>
<LI>trimeperidine.mp.</LI>
<LI>or/21-113</LI>
<LI>9 and 20 and 114</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-04-14 22:01:11 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-04-14 22:01:03 +1000" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-04-14 22:01:11 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>exp arthritis, rheumatoid/</LI>
<LI>(felty$ adj2 syndrome).tw.</LI>
<LI>(caplan$ adj2 syndrome).tw.</LI>
<LI>rheumatoid nodule.tw.</LI>
<LI>(sjogren$ adj2 syndrome).tw.</LI>
<LI>(sicca adj2 syndrome).tw.</LI>
<LI>still$ disease.tw.</LI>
<LI>(arthritis adj2 rheumat$).tw.</LI>
<LI>or/1-8</LI>
<LI>random$.tw.</LI>
<LI>clinical trial$.mp.</LI>
<LI>exp treatment outcome/</LI>
<LI>or/10-12</LI>
<LI>exp narcotic analgesic agent/</LI>
<LI>exp narcotic agent/</LI>
<LI>exp opiate agonist/</LI>
<LI>narcotic$.ti.</LI>
<LI>opiate$.ti.</LI>
<LI>opioid$.ti.</LI>
<LI>acemethadone.mp.</LI>
<LI>acetylmethadol.mp.</LI>
<LI>alfentanil.mp.</LI>
<LI>alphaprodine.mp.</LI>
<LI>anileridine.mp.</LI>
<LI>benzomorphan$.mp.</LI>
<LI>buprenorphine.mp.</LI>
<LI>butorphanol.mp.</LI>
<LI>carfentanil.mp.</LI>
<LI>codeine.mp.</LI>
<LI>dextromoramide.mp.</LI>
<LI>dextropropoxyphene.mp.</LI>
<LI>dezocine.mp.</LI>
<LI>diacetyl morphine.mp.</LI>
<LI>diamorphine.mp.</LI>
<LI>dihydrocodein$.mp.</LI>
<LI>dihydroetorphine.mp.</LI>
<LI>dihydromorphine.mp.</LI>
<LI>dimepheptanol.mp.</LI>
<LI>dionine.mp.</LI>
<LI>dipipanone.mp.</LI>
<LI>diprenorphine.mp.</LI>
<LI>dihydrohydroxycodeinone.mp.</LI>
<LI>dihydromorphinone.mp.</LI>
<LI>dynorphin.mp.</LI>
<LI>endomorphin.mp.</LI>
<LI>eseroline.mp.</LI>
<LI>ethylketocyclazocine.de.</LI>
<LI>ethylmorphine.mp.</LI>
<LI>fenoperidine.mp.</LI>
<LI>fentanyl.mp.</LI>
<LI>heroin.mp.</LI>
<LI>hydrocodon$.mp.</LI>
<LI>hydromorphon$.mp.</LI>
<LI>hydroxycodeinone.mp.</LI>
<LI>isocodeine.mp.</LI>
<LI>isonipecain.mp.</LI>
<LI>isopromedol.mp.</LI>
<LI>kaolin-pectin.mp.</LI>
<LI>ketobemidone.mp.</LI>
<LI>levallorphan.mp.</LI>
<LI>levodroman.mp.</LI>
<LI>levomethadryl.mp.</LI>
<LI>levomethadyl.mp.</LI>
<LI>levorphan$.mp.</LI>
<LI>meperidine.mp.</LI>
<LI>meptazinol.mp.</LI>
<LI>methadol.mp.</LI>
<LI>methadone.mp.</LI>
<LI>methadyl acetate.mp.</LI>
<LI>morphia.mp.</LI>
<LI>morphine.mp.</LI>
<LI>methynaloxone.mp.</LI>
<LI>nalbuphine.mp.</LI>
<LI>nocistatin.mp.</LI>
<LI>opium.mp.</LI>
<LI>oxycodein$.mp.</LI>
<LI>oxycodone.mp.</LI>
<LI>oxymorph$.mp.</LI>
<LI>pantopon.mp.</LI>
<LI>papaveretum.mp.</LI>
<LI>paracymethadol.mp.</LI>
<LI>paregoric.mp.</LI>
<LI>pentazocine.mp.</LI>
<LI>pethidine.mp.</LI>
<LI>phenazocine.mp.</LI>
<LI>phenbenzorphan.mp.</LI>
<LI>phenethylazocine.mp.</LI>
<LI>phenoperidine.mp.</LI>
<LI>pirinitramide.mp.</LI>
<LI>propoxyphene.mp.</LI>
<LI>protopine.mp.</LI>
<LI>pyrrolamidol.mp.</LI>
<LI>remifentanil.mp.</LI>
<LI>sufentan?l.mp.</LI>
<LI>talwin.mp.</LI>
<LI>tapentadol.mp.</LI>
<LI>thebaine.mp.</LI>
<LI>theocodin.mp.</LI>
<LI>tilidine.mp.</LI>
<LI>tramadol.mp.</LI>
<LI>trimeperidine.mp.</LI>
<LI>or/14-101</LI>
<LI>9 and 13 and 102</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-04-14 22:53:26 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-04-14 22:46:59 +1000" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-04-14 22:53:26 +1000" MODIFIED_BY="[Empty name]">
<P>#1           MeSH descriptor Arthritis, Rheumatoid explode all trees</P>
<P>#2           ((rheumatoid or reumat* or revmatoid or rheumatic or revmatic or rheumat* or reumat* or revmarthrit*) near (arthrit* or artrit* or disease* or condition* or nodule*)):ti,ab,kw in Clinical Trials</P>
<P>#3           (felty*):ti,ab,kw or (caplan):ti,ab,kw or (sjogren*):ti,ab,kw or (sicca):ti,ab,kw or (still*):ti,ab,kw in Clinical Trials</P>
<P>#4           (#1 OR #2 OR #3)</P>
<P>#5           MeSH descriptor Narcotics explode all trees</P>
<P>#6           MeSH descriptor Analgesics, Opioid explode all trees</P>
<P>#7           MeSH descriptor Morphine Derivatives explode all trees</P>
<P>#8           (acemethadone or acetylmethadol or alfentanil or alphaprodine or anileridine or benzomorphan* or buprenorphine or butorphanol or carfentanil or codeine or dextromoramide or dextropropoxyphene or dezocine or diacetylmorphine or diamorphine or dihydroetorphine or dimepheptanol or dionine or diprenorphine or dihydromorphinone or dynorphin or endomorphin or eseroline or ethylketocyclazocine or ethylmorphine or fenoperidine or fentanyl or heroin or hydrocodon* or hydromorphon* or isocodeine or isonipecain or isopromedol or kaolin-pectin or ketobemidone or levallorphan or levodroman or levomethadryl or levorphan* or meperidine or meptazinol or methadol or methadone or methadylacetate or morphia or morphine or methylnaloxone or nalbuphine or nocistatin or opium or oxycodein* or oxycodone or oxymorph* or pantopon or papaveretum or paracymethadol or paregoric or pentazocine or pethidine or phenazocine or phenbenzorphan or phenethylazocine or phenoperidine or pirinitramide or propoxyphene or protopine or pyrrolamidol or remifentanil or sufentanil or sufentanyl or talwin or tapentadol or thebaine or theocodin or tilidine or tramadol or trimeperidine or dihydromorphine or hydroxycodeinone or levomethadyl or dihydrocodeinone or levomethadyl or dihydrocodein* or dihydrohydroxycodeinone or dipipanone):ti,ab,kw in Clinical Trials</P>
<P>#9           (narcotic*) or (opiate*) or (opioid*):ti in Clinical Trials</P>
<P>#10         (#5 OR #6 OR #7 OR #8 OR #9)</P>
<P>#11         (#4 AND #10)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;Reason for exclusion: insufficient data for meta-analysis (n=4)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 of studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;33 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1172 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1172 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;1324 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1139 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;22 full-text articles excluded:&lt;/p&gt;&lt;p&gt;Mixed or incorrect population (n=11)&lt;/p&gt;&lt;p&gt;Incorrect comparison (n=6)&lt;/p&gt;&lt;p&gt;No pain outcome measure (n=2)&lt;/p&gt;&lt;p&gt;Published as abstract only (n=2)&lt;/p&gt;&lt;p&gt;Multiple publications (n=1)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>